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ABSTRACT
Herpetic stromal keratitis (HSK) is an immunoinflammatory corneal lesion caused by
herpes simplex virus (HSV) infection. One of the dire consequences of which is blindness
resulting from tissue destructive immunopathological reaction in corneal stroma. The lesion is
considered to be orchestrated mainly by CD4+ T cells of Th1 phenotype. Studies on two animal
models viz. immunocompetent and immunodeficient, shed light on the issues on specificity of the
cells which at least in immunocomprised TCR transgenic animals were shown to be activated in a
bystander manner. However, initial infiltration by innate immune cells in response to replicating
virus set the stage for the chronic inflammation in the corneal stroma. Paradoxically, these cells
are also critical in the control of virus in the cornea.
The first part (Part I) of this dissertation focuses on the understanding of HSV-1 induced
immunoinflammatory processes in the cornea and trigeminal ganglia including the secondary
lymphoid tissues and the involvement of regulatory mechanisms. The next three parts (Part II-IV)
focus on the control of the inflammatory lesion and anti-inflammatory mechanisms that are
activated following virus infection in the lymphoid organs and cornea. Results in Part II evaluate
the immunotherapeutic potential of regulatory T cells in controlling the progression of the
inflammatory lesions after ocular HSV infection. Results of the third section show that
sequestration of T effector cells in the lymphoid organs and limited access to site of inflammation
using a drug FTY720 after HSV infection resulted in diminished severity of SK and expansion of
antigen-specific regulatory T cells that could contribute to the diminution of lesion severity. The
fourth section describes the role of a previously unexplored inhibitory interaction between a Th1
specific cell surface marker, TIM-3 and its ligand galectin-9 in the causation of the viral induced
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corneal immunopathology. The administration of galectin-9 seemed to be an effective approach to
terminate Th1 responses and promote regulatory cells activity thereby controlling the severity of
lesions.
In this study, experiments were designed to control the progression of the ongoing
inflammatory reaction in the cornea in order to evaluate some of the therapeutic strategies for
HSK.
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PART-I
BACKGROUND AND OVERVIEW

Etiology and epidemiology of SK
Herpetic Stromal Keratitis is an immunoblinding ocular lesion in normally transparent
cornea and is caused by herpes simplex virus (HSV) infection. It is the most common cause of
infectious blindness in the developed world. As per recent studies, the incidence of the disease
lies between 4.1 -20.7 /100,000 of the population per year in the western world (1). Recent
changes in the life style and behavior among the population presents a typical incidence pattern
of herpes viral infections with more people being tested seropositive for HSV-2 than for HSV-1
(2). The incidence of HSK in the younger population, where it tends to be more severe, is on the
rise in developing countries and is further complicated by factors such as malnutrition, coinfections and lack of accessibility to available treatments (3). Ocular lesions in human are
mostly caused by recurrent activation of HSV 1 from the trigeminal ganglion (TG) and reflects
the interaction between viral and host factors (2). The incidence of HSK by primary infection is
three times lower than by recurrent infection. Because of unknown reasons, frequent cases of
HSV 2 induced HSK occur in neonates but such are rare in adult population.
HSV can establish both productive and latent infection depending on the cell type
infected. The non-neuronal cells allow the replication of viral genome while in sensory neuronal
cells replication is limited and the virus tries to establish latency that can be life long. Classically,
the life cycle of HSV in the host is divided into four stages: entry, spread, establishment of
latency and reactivation. After the primary infection of the skin or mucosal surfaces with HSV, it
spreads to the neuronal cell bodies where latency is established (4). Recent studies have
established that maintenance of latency is dominantly achieved by both viral encoded factors
such as miRNAs (5) or the host immune mechanism involving CD8+ T cells responses (6).
Depending upon the psychological, physical or the immune status of host, virus gets periodically
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activated from latency in TG and released to the periphery. After reactivation, virus has a
tendency to migrate to the initial site of infection and causes different types of painful
inflammatory reactions depending on the involvement of tissue. But if the site of predilection
happens to be eye, it causes either a sub-clinical or clinical inflammation in the epithelium that
could be mitigated by anti-virals or a more severe chronic immunoinflammatory syndrome
especially in the stroma where the reaction is called herpetic stromal keratitis or HSK that
impairs vision and may lead to blindness if left unattended (3). HSV infections could also
potentially result in viral retinitis and/or encephalitis in both immunosuppressive and
immunocompetent individuals (3). Major symptoms of HSK lesions includes but not limited to
corneal necrosis, ulceration and scaring, stromal edema and neovascularization that may
necessitate corneal transplantation (7). These lesions are primarily orchestrated by CD4+ T cells,
the antigen-specificity of which remains poorly defined.

Animal models and pathogenesis of SK
Most of the studies directed to elucidate the pathogenesis of HSK were performed on
animal models for human HSK. While for primary infection, mouse is the most studied animal
model, the rabbit is the preferred animal model for recurring infection. However similar type of
lesions occurs after primary or the recurrent infection (8). Understanding progressing events that
finally lead to corneal inflammation has mainly come from primary ocular infection in mice.
Several strains of mice including both immunocompromised and immunocompetent animals
such as BALB/c, C57BL6, CAL-20, 129/SVEV have been described for studying HSK (9). In
immunocompetent animals SK lesions are evident within 6-7 days after ocular infection with
HSV 1 that peak in severity between 15-21 days. The lesions are primarily contributed by CD4+
3

T cells that are detected in abundance at day 7-8 pi and most of which are likely to be HSV
reactive. Another model is a TCR transgenic mice on a RAG–/– background, which were shown
to develop SK upon ocular infection with HSV, even though their CD4+ T cells were almost all
reactive with OVA323-339 peptide and not detectably cross-reactive with HSV antigens (10). The
CD4+ T cells in the ocular lesions of such animals were shown to react with the KJ1.26 mAb noted
by others to react with the TCR of H-2d CD4+ T cells that recognize the OVA323-339 peptide (11).
Since this KJ+ TCR had no demonstrable reactivity with HSV, it was thought that the activation
of KJ+ CD4+ T cells was not TCR mediated but involved activation by one or more cytokines
(12). This model was referred to as a bystander model of SK (13). Yet another model that has
been characterized is SK induced in SCID animals after reconstitution with CD4+ but not CD8+
T cells isolated from either HSV immune or naïve animals (14-16). All these animal models
present typical SK lesions characterized by corneal haze, edema, necrosis, ulceration and
neovascularization.
Ocular infection with HSV 1 in immunocompetent animals is followed by initial
replication of virus especially in the corneal epithelium for up to 5-6 days. Live viral particles
and the transcribed mRNA copies of viral genes could be detected from the corneal swabs during
this time but not beyond 7 days post infection using conventional viral titration and RT-PCR
assays respectively (1). However, viral DNA could be detected in the cornea even up to 21 days
post infection (pi) the time when the disease is at its peak and spontaneous healing may start in a
minority of animals. The nature and pathophysiological significance of the persisting viral
genomic DNA species in terms of their transcriptional and translational efficiency to make viral
proteins is not yet elucidated. The studies focused on these aspects would shed light on some of
the previously unknown players in the causation of SK. After the initial phase of viral infection
4

and replication in the cornea, there is a prominent infiltration of inflammatory cells near the
corneal epithelium that mainly consists of neutrophils (PMN) (17). These cells could potentially
exert anti-viral defense by producing nitric oxides, reactive oxygen species, TNF-α, IFN-γ or
perhaps just by engulfing viral particles. Furthermore, the kinetics of their infiltration correlated
with the clearance of replicating virus from the cornea as shown in Fig.1.1 (All figures are
supplied in appendix following the main part). Other studies where neutrophils were depleted
prior to ocular HSV infection showed a delay in viral clearance from the cornea (18). In addition
to their role in viral clearance, they may also provide conducive conditions for the ensuing
inflammatory response by releasing mediators such as IL-1β, IL-8 (MIP-1α) and IL-12 and TNFα. Neutrophil secreted NO could unmask corneal antigens that can be continuous source for the
influx of reactive T cells. The matrix metelloproteinases such as MMP-9 breaks stromal matrix
and along with neutrophil or perhaps stromal cell secreted VEGF-A contribute to the
neovascularisation of usually avascular cornea. VEGF-A protein expression is evident in the
cornea within 24 hrs and is mainly produced by epithelial cells or the stromal cells after ocular
HSV infection. IL-1 and IL-6 produced by infiltrating inflammatory cells are the subsequent
inducers of VEGF. Inhibition of angiogenesis by targeting MMP-9 and VEGF by siRNA
approach were shown to reduce the extent of neovascularization (19, 20). Some additional
angiokines such as bFGF, E-L-R motif containing chemokines (MIP-2) are also upregulated in
cornea after HSV infection (21). In addition to PMNs, other cells such as DCs, NK cells, γδ-T
cells, macrophages etc. could contribute both towards viral clearance and the subsequent
inflammation by secreting type I IFNs, and other cytokines as well as chemokines such as IL-6,
IL-1β, IL-12, MIP-2, TNF-α, IFN-γ, IL-23, IL-17 etc (1). Once the vascular bed is formed, there
is continuous infiltration of cells because of leakage of newly formed vessels. IL-1 and IL-6
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were shown to be the critical cytokines to initiate the subsequent inflammatory events and could
be produced by epithelial cells initially after viral infection. HSV DNA and perhaps some of its
other components expressing PAMPs can activate PRR such as toll like receptors (TLRs)-2,4
and 9 on the innate cells which provide stimulation for the activation of the NFκB pathway (22) .
CpG motifs derived from viral DNA in the cornea could stimulate TLR 9 and induce IL-1 and
IL-6 that contribute to the immunopathological lesions along with an efficient induction of
adaptive immune response (23). IL-6 could be produced by un-infected cells by IL-1 stimulation
in a paracrine manner which in turn trigger MIP-2 (also known as CXCL8) production that is
involved in the attraction of PMNs. COX-2, is another important mediator of inflammation that
could be induced by IL-1 in the cornea and acts through production of PGE2 (24). Recent studies
have shown the important role of TNF-α in the causation of SK with animals lacking in this
cytokine were unable to control the virus in cornea and thus exhibited enhanced lesion severity
(25).
IL-12 produced by PMNs, macrophages and Langerhans DCs was shown to be another
important candidate cytokine involved in the pathogenesis of SK (26, 27). It is involved in the
downstream production of IFN-γ by macrophages, NK cells, neutrophils and CD4+ T cells. Both
proinflammatory and anti-inflammatory activities have been attributed to IFN-γ. It aids in the
PMN influx by upregulating PECAM-1 and ICAM-1 on corneal epithelial cells (28, 29),
endothelium cells and keratocytes needed for the exit of inflammatory cells. It also helps to
prime the CD4+ T cell responses by up regulating MHC II on antigen presenting cells. The most
important anti-inflammatory activity of IFN-γ is attributed to its potential of inducing antiangiogenesis factors including, but probably not limited to, IP-10 (30). Its role in promoting
Foxp3+ regulatory T cells induction was also described recently (31-33). IL-23/IL-17 axis is
6

another recently identified pathway involved in pathogenesis of various types of autoimmune
inflammatory lesions. IL-23 produced by innate cells such as DCs is responsible for the
stabilization of cells with the Th17 phenotype. IL-17 produced by inflammatory Th17 or perhaps
fibroblast or neutrophils help recruit more PMNs. The role of IFN-γ producing Th1 cells is well
studied in SK pathogenesis but a precise role of Th17 cells has not yet been described. In mouse
SK lesion CD4+ T cell outnumbers CD8+ T cells but the reasons for their preferential
accumulation remains unclear (34). The inflammatory reaction in the trigeminal ganglion has a
preponderance of CD8+ T cells in addition to CD4+ T cells. The antigen-specificity of CD4+ T
cells that infiltrate cornea remains largely unknown because of a lack of specific CD4+ T cells
epitope derived from HSV or the tetramer. It is anticipated that CD4+ T cells that infiltrate into
cornea initially constitute a population enriched in HSV reactivity. Later on lesions would be
dominated by bystander cell populations. Because of less stringent requirements of antigenic
stimulation of Th17 cells (35) , it is possible that the role of these cells in the pathogenesis of SK
predominates in the later stages of inflammation where viral antigen availability is limited. Thus,
one valid hypothesis could be that the acute phase is mainly dominated by Th1 cells while the
chronicity of lesion is maintained by Th17 cells. Some of our initial observations support this
hypothesis (unpublished observations).

Current Treatment options
Anti-virals and anti-inflammatory agents
SK is a sight-threatening and difficult to control inflammatory reaction in the cornea.
Currently, there is a dearth of agents which are approved for treating keratitis. Major classes of
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drugs in use are either anti-virals or/and anti-inflammatories which include corticosteroids as
well as non-steroidal anti-inflammatory drugs such as Cyclooxygenase-2 (COX-2) blockers (9,
36, 37). However, neither is beyond adverse effects. Viral species develop resistance to the antivirals especially in immunocompromised individuals if used for prolonged periods of time (38,
39). Similarly use of corticosteroids might result in numerous adverse effects (40, 41). In some
patients corticosteroid may enhance HSV-1 replication thereby exacerbating HSK lesions (42).

Future therapies
Targets for future therapies have mainly come from animal studies. Some of the studies
in the mouse model of HSK have demonstrated that cytokine and chemokine blockers such as
the IL-1 receptor antagonist are effective in controlling the severity of lesions (43). Inhibiting
the transcription of genes for angiogenesis factor VEGF-A using siRNA approach was shown to
be effective in reducing HSK lesions in the mouse (20). However, the mechanism by which it
worked remains poorly understood. A recent report suggested a non-specific inhibition of
angiogenesis by all ds RNA segments which stimulate TLR-3 and thereby induce production of
IFN-γ (44). IFN-γ has been shown to have anti-angiogenesis activities. Other strategies that
targeted the angiogenesis response included use of a recombinant Salmonella typhimurium
containing a plasmid that encoded VEGFR-2 (45). This strategy induced anti-VEGFR-2 CD8+ T
cells that targeted pathological endothelial cells and inhibited neovascularization. However, the
adverse effects because of non-specific killing of endothelial cells are expected. Several other
approaches that made use of some components of HSV genome such as gB, gD (46-49) or the
live mutant of vhs-/ICP8- HSV strain (50) have been shown to reduce the incidence of HSK.
Various vaccine strategies along with the use of modifiers such as CpG, heat shock proteins
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(hsps) etc have been described that enhanced the efficacy of HSV specific immune response (51,
52). The importance of vaccines has been envisaged because none of the anti-virals available is
able to prevent the establishment of latency. Therefore, there is an increasing need of designing
newer therapeutic vaccines and study their efficacy in terms of neurosurveillance and preventing
reactivation of virus from the TG. A therapeutic agent BAY 57-1293, a helicase-primase
inhibitor when used orally on daily basis showed some effects on reducing the reactivation of
virus from latent TG and a subsequent dampening effects on virus replication in cornea that
reduced the lesion severity.
Other recently identified novel immunotherapeutic molecules are being studied to add to
the options for treating SK. One of them is apoprotein E (apopE) mimetic dimer peptide
(apoEdp) and was shown to possess anti-viral and anti-inflammatory activities against ocular
HSV infection when topical treatment begun 24 hr post infection and continued until day 10
(53). Another agent include topical treatment with >0.1% of cyclosporine that had some level of
efficacy in diminishing the corneal haze in mice (54).
Regulatory T cells as an immunotherapeutic
Another subset of T lymphocytes that infiltrate the cornea is CD4+CD25+Foxp3+
regulatory T cells (Tregs). In addition to other mechanisms such as the cytokine IL-10 (15, 55)
Treg are shown to be involved in controlling the ongoing inflammatory processes in the cornea
(15). In addition, these cells might help in the resolution of the clinical lesions. Studies suggest
that depletion of Treg from the mice prior to infection results in more severe SK lesions (15).
Sakaguchi et al.’s seminal observations in the mid-1990s (56) reawakened interest in Tregs and
opened up the prospect of using these cells immunotherapeutically. Most of the Foxp3+ Tregs are
considered to be thymus-derived and are largely reactive to a range of self Ags (57). These cells
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are involved in preventing and constraining autoimmunity, however the cells of the same
phenotype may also participate in responses to foreign antigens and tumors. Indeed, regulatory
cells may function beneficially to control tissue damage caused by auto reactivity, allergies and
allotransplants, as well as responses to many tissue damaging pathogens (55). For therapeutic
purposes, it would be preferable to use Tregs of known Ag specificity so as to increase potency
and avoid potential side effects of inhibiting desirable immune responses. Some have expanded
specific self-reactive Tregs in vitro and demonstrated in vivo efficacy using adoptive transfer
approaches. This has been a “hot topic” recently in the Treg field since it is particularly relevant
in terms of devising useful ways of manipulating the response therapeutically.
Strategies to cause conversion of conventional cells into Tregs
That the conversion of conventional CD4+CD25- T cells into CD4+CD25+Foxp3+ Tregs
can be accomplished was appreciated some time ago by the Horwitz and Wahl groups who
showed that TGF-β stimulation was a key event for the conversion process. Thus, the addition of
TGF-β and IL-2 in TCR stimulated naïve CD4+ T cells either from human or mice can result in
Foxp3+ Tregs induction (58, 59). When such converted cells were administered in vivo, they
could suppress the proliferation of naïve CD4+ T cells and prevented dust-mite induced allergic
pathogenesis in lungs (59). The feasibility of in vivo conversion of Foxp3+ regulatory T cells
from conventional CD4+T cells in periphery was shown in a TCR tg mouse model in which
minute doses of a peptide were directed to certain types of dendritic cells (DCs) which were
minimally activated (60, 61). Addition of TGF-β and IL-2 enhanced the conversion efficiency.
These cells could further be expanded by immunization with the cognate antigen and were highly
suppressive. A recent study suggested that exosomes like particles (ELPs), which are also a
source of TGF-β, released from the thymus could play an important role in the peripheral
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generation of Tregs (62). Foxp3 could be induced in Foxp3-CD4+T cells by administration a
copolymer-1 (COP-1) in patients suffering from multiple sclerosis. The administration of COP-1
expanded regulatory T cells and these cells exhibited potent suppressive activity. The mechanism
by which the induction of Foxp3 could be achieved was found to be dependent on the production
of IFN-γ and TGF-β (63). A paradoxical situation where pro-inflammatory cytokines could
induce anti-inflammatory regulatory T cells put forward a paradigm that the body has an inherent
mechanism of dealing with excessive inflammation. The role of IFN-γ in induction of Foxp3 was
also confirmed in other studies (31-33). The induction and enhancement of suppressive activity
of Tregs by IFN-γ was found to be dependent upon STAT-1 signaling and production of NO (32,
64). NO is also produced by inflammatory innate cells such as neutrophils and myeloid
suppressor cells (65, 66). It would be interesting to investigate if these cells have some role in the
generation, maintenance or the expansion of Tregs. A role of another proinflammatory cytokine,
TNF-α, in promotion of Treg responses was described recently (67). Tregs have been shown to
have higher expression of TNFR-2 and the signal transduced by TNF-α in Tregs enhanced their
proliferation and suppressive activity by up-regulating the expression of IL-2 receptor alpha
chain (CD25) and Foxp3 (67, 68).
In addition to TGF-β, other anti-inflammatory molecules such as Thrombospondin-1
(TSP) when interacts with its CD47 receptor promotes the generation of human regulatory T
cells (69). TSP is predominantly secreted by platelets and APC, and plays a major role in
inhibiting angiogenesis, tumor cell growth and promoting apoptosis (70). Various domains of
TSP exert both stimulatory and inhibitory effects on T cells via two TSP receptors, i.e., α4β1 and
CD47, respectively. However, intact TSP is predominantly an inhibitor of TCR signal
transduction (71) and IL-12 responsiveness of naive and adult T cells (72). TSP has also been
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shown to be the main activator of TGF-β (28). Ligation of Thrombospodin to CD47 expressed on
activated CD4+ T cells rendered them anergic and imparted a regulatory phenotype that was
accompanied by upregulation of CTLA-4, Foxp3, GITR, CD25 and OX40. The suppressive
mechanism by these cells was contact dependent but TGF-β independent (69).
Intravenous immunoglobulin (IVIG) therapy is practiced as tolerance inducing strategy
but recent studies have shown that one of the mechanism by which these therapeutic regimen
could achieve tolerance is by inducing Foxp3+ regulatory T cells (73). The presence of Treg
epitopes also called as ‘Tregitopes’, in the constant region of Ig provided some explanation as to
why Tregs were expanded in these patients. Tregitopes could stimulate the proliferation of Tregs
(74). Administration of tryptophan catabolizing enzyme, indoleamine 2,3-dioxygenase (IDO)
expressing leukemia cells in the spleens could expand Treg population thereby inducing a state
of tolerance (75).
An essential role of Tregs in maintaining maternal tolerance to the fetus during
pregnancy has been explored recently (76, 77). Estrogen is one of the hormones which is highly
expressed during pregnancy and plays an important role in establishment of pregnancy by
activating blastocyst and initial implantation (77). Conventional CD4+CD25- cells expressed the
receptor for estrogen (ER). When estrogen is bound to ER on these conventional T cells, it
induced Foxp3+ expression and the cells attained the ability to suppress proliferation of TCR
stimulated responder CD+4 T cells in in vitro assays by producing TGF-β or IL-10. The
conversion process was inhibited when a specific inhibitor (ICI 182780) of estrogen receptor was
added in the cultures (76-78). These studies put Tregs on the center stage for maintaining the
maternal tolerance to fetus.
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Another immunomodulating neuropeptide, α–melatonin stimulating hormone (α-MSH)
was shown to promote the generation of regulatory T cells in synergy with TGF-β (79, 80). The
cells generated by this protocol produced TGF-β and exhibited suppressive activity in an antigen
specific manner when transferred in vivo and prevented progression of experimental
autoimmune uvoretinitis (EAU).
Role of antigen presenting cells and co-stimulatory molecules in the conversion process
Almost all of the conversion studies have made use of APCs or the micro beads coated
with antibodies to co-stimulatory molecules in the cultures of TCR stimulated CD4+ T cells,
however, the requirement of individual costimulatory or inhibitory interaction pair between
stimulated T cells and APCs remained largely unexplored until recently. Studies in recent years
have investigated the role of some of the costimulatory or inhibitory interaction pair of molecules
in the peripheral generation of Tregs. The first molecule that was shown to have a pivotal role in
the conversion process was B7. Thus, conversion of transferred conventional CD4+ T cells into
CD4+CD25+ Tregs could be achieved in wild type congenic animals but not in B7-/- animals
(81). Another inhibitory molecule Cytotoxic T lymphocyte antigen-4 (CTLA-4), a member of
CD28-family of molecules and is expressed on TCR and anti-CD28 stimulated CD4+ T cells.
The major function of this molecule is to suppress the functioning of CD4+ T cells by competing
with CD28 for binding to B7.1 and B7.2 molecules (82) and decreasing the contact time of APCs
with CD4+ T cells (83). CTLA-4 Ig fusion protein has been used as an immunosuppressive agent
in some autoimmunities such as rheumatoid arthritis and transplant rejection. Recently, it has
become evident the addition of CTLA-4xIg in TCR stimulated cultures could convert
CD4+CD25- T cells into CD4+CD25+Foxp3+ Tregs having potent suppressive activity.
Furthermore, Tregs population expanded in vivo when CTLA-4Ig was administered (84). The
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conversion and the expansion process were dependent on the presence of APCs and inhibited by
the addition of anti-B7.2 blocking antibody. This study further attested to the involvement of B7
molecules in the conversion process. PD-1 and PDL-1 inhibitory signal was also found to play
important role in the conversion of conventional CD4+ T cells into Tregs ((85),our unpublished
observation). Thus, it was shown that CD8a+ DCs were more efficient than CD8a- DCs in
converting CD4+T cells into Tregs. It was further shown that DCs taken out from PDL-1
knockout animals were less efficient in converting TCR stimulated CD4+CD25- T cells into
CD4+CD25+Foxp3+ regulatory T cells in presence of TGF-β. Furthermore, administration of
anti-PDL1 but not anti-PDL-2 antibody significantly inhibited the induction of Foxp3 ex vivo
(85). The overall numbers of Foxp3+ Tregs were not found to be significantly different in either
PD-1 or PDL-1 knockout animals as compared to wild type counterparts ((86), our unpublished
observations). This observation could be explained in terms of the operation of compensatory
mechanisms, which could have enhanced the Treg numbers, in the absence of signaling through
PD-1. Some specialized subsets of CD103+DCs isolated from the gut express enzymes such as
retinal dehydrogenase that permit the conversion of vitamin A into retinoic acid (87-89).
Furthermore, retinoic acid along with TGF-β act as a factor that drives the conversion of TCR
stimulated Foxp3- conventional T cells into Foxp3+ regulatory cells. Retinoic acid may also drive
the conversion of human cells although in this instance the co-addition of TBF-β is not required
(90). Apart from promoting the conversion of Tregs, antigen presenting cells through ligation of
some co stimulatory pair of molecule inhibit the process of conversion. Thus, OX40/OX40L
interaction pair inhibited TGF-β dependent conversion of TCR stimulated CD4+ T cells into
Tregs. At the same time it promoted the proliferation of effector T cells (91). Another molecule,
galectin-9, a natural product of many cell types has been found to have a Treg generation
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promoting activity. Thus, animals lacking galectin-9 had reduced numbers of Tregs and addition
of galectin-9 promoted TGF-β induced conversion of conventional T cells to become Foxp3+
(92). In part IV of this dissertation, we have shown that galectin-9 could promote Treg
generation even in the presence of inflammatory milieu.
Until recently, neurons were thought to have an immuno-regulatory functions but their
expression of B7 and TGF-β provided a mechanistic explanation of their being highly immunoregulatory. Thus neurons expressing B7 and TGF-β could confer a regulatory phenotype to
interacting CD4+ T cells by inducing Foxp3 in them (93).
Involvement of T cell intrinsic mechanisms in the conversion process
TGF-β signaling in naïve cells stimulated through their TCR is transduced by either of
SMAD proteins (SMAD2, 3 or 4) or through p38 MAP kinase pathway. Signalling through
SMAD proteins led to the upregulation of all TGF-β dependent genes and thus imparted T cells a
regulatory phenotype (94). At the same time signaling through TGF-β also activated the p38
MAP kinase pathway and inhibition of this pathway by specific inhibitor, SB203580, prevented
the conversion of CD+CD25- T cells into Foxp3+ Tregs (94). However, in already differentiated
Tregs, this treatment did not affect the suppressive activity suggesting that signalling through
p38 is important in the initial stages of differentiation. Another group of proteins that were found
to have an important role in promoting expansion of regulatory T cells are members of GTP
binding proteins family. These include protein product encoded by Ras genes (N-Ras, K-Ras,
and H-Ras) and have diverse intracellular signaling functions including the control of cell
differentiation, proliferation, growth, and apoptosis (95). These proteins are considered as
switch-signals and act by cycling between inactive-GDP or active-GTP conformations (96). The
final signaling event through these proteins is activation of ERK/MAP kinase pathway that in
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turn activates T cells. The inhibition of N-Ras and K-Ras genes by shRNA and small molecule
inhibitors such as farnesylthiosalycylic acid, led to increased expression of Foxp3 in CD4+ T
cells that was accompanied by enhanced suppressive activity (97). An importance of another
signaling molecule STAT 3 in the conversion of Tregs and maintenance of their activity was
realized recently where ablation of STAT-3 using shRNA or neutralizing antibody led to
decreased conversion of CD4+CD25- T cells into Tregs and animals failed to prevent occurrence
of acute graft-vs-host disease (98). A dominant role of CTLA-4 in maintaining the suppressive
activity of CD4+CD25+Foxp3+Tregs have been demonstrated recently (99). Thus selective
depletion of CTLA-4 gene in Tregs resulted in fatal autoimmune disease in animals (99). GRAIL
(gene related to anergy in lymphocytes), a ubiquitin-protein necessary for the induction of anergy
in CD4+ T cells was found to be highly up regulated in Foxp3+ Tregs and the forced expression
of this molecule in T cell line could impart them a suppressive phenotype in the absence of
Foxp3 expression (100)
Signalling through IL-2 has been shown to be a critical event in the generation of Tregs
(101). In the absence of IL-2 signalling other cytokines such as IL-7, and IL-15 can have some
compensatory role in the promotion of Treg generation and expansion (102).
Epigenetic control of Foxp3 locus in regulatory T cells
The role of the microenvironment constituted by cytokines such as TGF-β, IL-2, IFN-γ,
TNF-α etc. in the induction of Foxp3 in a cell type that is committed to become regulatory is
well known from the studies over many years (59, 60). But little is known about the stability of
phenotype attained by these cells as compared to thymus derived natural Tregs. The epigenetic
mechanism that include histone modifications and selective demethylation in CpG motifs have
been shown to play pivotal role in stable cellular lineages of one type or the other. These events
16

impart heritability fixed expression patterns of distinct genes in the cell (103-105). The
involvement of these mechanisms in the commitment of regulatory T cells is not clearly known
at this time and is a current area of active research in the biology of Tregs. Some studies have
attested to the importance of DNA demethylation, acetylation of histone proteins such as H3, H4
and trimethylation of H3 in the conserved regions in foxp3 locus in Tregs but not in conventional
CD4+CD25- cells (106). These modifications were also shown by human CD4+CD25hi Tregs
suggesting the evolutionary importance of these events that allow persistent expression of Foxp3
and thus a regulatory phenotype. TGF-β induced Tregs show a weakly demethylated CpG motifs
within conserved region of foxp3 locus that might not impart them a stable phenotype. Futher
support for these studies came from recent observation where the use of agents that either
inhibited DNA methylation of CpG motifs such as azacytidine or deacetylation of certain histone
protein such as Trichostatin A (TSA) or valproic acid (VPA). This resulted in promotion of
Foxp3 expression even in absence the of TGF-β but also enhanced their suppressive activity
(107, 108). The appropriately modified foxp3 gene further regulates Treg specific characteristics
such as anergy and suppressive functions by suppressing transcriptional and promotor binding
activity of protein such as activator protein 1 (AP-1) by interacting with phosphorylated c-Jun
(109). In adition, the functional Foxp3 protein in a cell actively repress transcription of genes by
recruiting distinct histone acetyl transferases and histone deacetylases (110). In Tregs, foxp3
physically interacts with transcription factors such as acute myeloid leukemia 1 (AML-1) and
Runt-related transcription factor 1 (Runx1) which are required for the transcription of IL-2 and
IFN-γ and thus regulate the production of these cytokines (111).
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Resistance of Tregs to T cell depleting regimens
Many studies have advocated the differential susceptibility of Tregs to depletion and
apoptosis inducing strategies. Thus, it was shown that TCR stimulated Tregs were less
susceptible to Fas-Fas-L induced apoptosis than TCR stimulated conventional CD4+CD25- T
cells. However, the susceptibility followed a reverse trend for naïve cells (112). The efficacy of
anti-thymocyte globulin therapy for depleting peripheral lymphocytes in order to maintain
tolerance in the patients suffering from auto immunities or those who received transplants has
been demonstrated. This therapy depleted T effector cells but the the population of Tregs was
spared (113). Furthermore, ex vivo treatment with anti-thymocyte globulin induced and
expanded Treg populations (114). Nur77, a protein of the nuclear receptor family, has been
shown to promote apoptosis of thymocytes during negative selection of autoreactive thymocytes.
However, Tregs were found to be resistant to Nur77 mediated apoptosis (115). Another reagent
that has been studied for inducing tolerance in autoimmiunities such as EAE and type 1 diabetes,
is anti-CD3 monoclonal antibody. Its administration in patients reduced the streptozocin induced
diabetes and Th1 type of immune response at the same time it increased the expression of latency
associated peptide on CD4+ T cells (116). The use of this antibody not only prevented the
development of diabetes but also reversed the disease (117). A very recent study on lupus, an
auto-antibody mediated autoimmune disease, reported the efficacy of nasal administration of
anti-CD3 antibody in inhibiting the progression of the lesions development and at the same time
inducing IL-10 secreting CD4+CD25-LAP+ Regulatory T Cell (118).
Strategies to inhibit the suppressive activity and the conversion process of Tregs
Regulatory T cells are one of the important players in the maintenance of peripheral
tolerance and preventing excessive tissue damage as a result of an inflammatory reaction.
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However, there are situations where their activity needs to be regulated. Enhancing tumor
immunity, anti-microbial immune response, vaccine efficacy etc. are some of the examples
where excessive Treg response might hinder in the generation of effective immune response.
Therefore, under such circumstances, the activity of Tregs needs to be blunted. Some of the
factor that have been shown to negatively regulate Tregs are cytokines IL-6, IL-12, IL-21 etc
(119, 120). Curiously, adding inflammatory cytokines such as IL-6 in cultures thought to be
suitable for generation of Tregs resulted in the induction of T cells that produced IL-17 and were
found to be responsible for excessive CNS inflammation (121). Additionally, it was shown that
IL-21 could initiate an alternate pathway of induction of Th17 cells in the absence of IL-6 and
also inhibited the activity of Tregs (122). Signaling through some TLRs such as TLR-9 and
TLR4 abrogated the activity of Tregs (119, 123). Accordingly, it was shown that gut micro floral
CpG DNA by activating TLR-9 inhibit the process of Foxp3 generation and enhanced the
immune response to oral infection (123). AKT was shown to be a critical pathway that inhibited
de novo differentiation of regulatory T cells by changing the transcription signature molecules
associated with the Tregs phenotype in undifferentiated CD4+ T cells. It did not affect the Foxp3
expression in already differentiated cells (124). The forced expression of AKT or the agents
which could increase its expression could be used to reduce the numbers of Tregs. Another
pathway that was shown to inhibit Treg function and differentiation is OX40/OX40L pair (125).
Thus it was shown that CD4+ T cells isolated from OX40L Tg mice were highly resistant to
conversion into Foxp3+ Tregs and these animals have large numbers of memory T cells
(CD44hiCD62L-) which were not only resistant to conversion into Tregs but actively inhibited
the conversion of naïve CD4+ T cells to become Foxp3+ by inducing producing IFN-γ and
inducing T-bet. In addition, some studies showed that function of Tregs could be abrogated by
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inducing signaling through OX40L (125). Accordingly, it was shown that administration of antiOX40 agonist antibody into tumors, which is enriched in OX40L+ Foxp3+ Tregs, led to rejection
of tumors provided sufficient numbers of CD8+ T cells were present

(126). Signalling

transduced through some of the T cell surface receptors could modulate the conversion process
and the activity of Tregs. It was shown that an agonist antibody against TIM-1, a T cell specific
surface marker deprogrammed the Tregs, inhibited the conversion of CD4+CD25- cells into
Tregs and enhanced the function of effector T cells thereby preventing allogenic transplant
tolerance (127). In a recent study in renal transplant patients, use of a pharmacological agent,
calcineurin inhibitors (CNI), reduced the numbers of Tregs in peripheral blood while rapamycin
treatment preserved their numbers (128).
The agents described in this section could be used to turn the activity of Tregs off in
situations where they have undesirable effects.

Conclusions
SK is a chronic immunoinflammatory lesion in cornea with a complex pathogenesis.
Discoveries of novel pathways and molecular participants in the pathogenesis would provide
new targets for designing therapeutics. Based on the previous knowledge of the key player and
events involved in the development of SK, strategies that target one or more of the key events
need to be investigated. Some of these approaches include inhibition of excessive immune
response generation, limiting the access of T effectors to the inflammatory sites in the cornea by
preventing their exit from lymphoid organs, or delivering an inhibitory or lethal signal to the
cells at the site of inflammation to treat the disease.
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The work described in this dissertation evaluated the effects of some of these strategies
on modulating SK lesion. Tregs specific to a well know OVA antigen were generated and
characterized. The functional polyspecificity of in vitro generated Tregs was evaluated in HSV
induced immunopathology in three separate models of SK. In a second approach cells were
sequestered in the lymphoid organs using a small molecule, FTY720, that acts as an agonist to
sphingosine receptors and temporarily down regulates their expression so that cells are
sequestered in lymph nodes and do not migrate to inflammatory site in the cornea. The prolonged
use of this drug generated antigen-specific Tregs that were also shown to regulate the severity of
SK lesion previously (15) . In the last approach cells were induced to undergo apoptosis in vivo
at the site of inflammation using a recently discovered molecule, galectin-9, that delivers a lethal
signal to Th1 effector cells through a surface molecule TIM-3 and a positive signal to regulatory
T cells. These approaches could be used individually or in combination with other existing
therapies ro resolve SK with minimal unwanted side effects.
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Clinical phase

Figure 1. 1 Principal events in herpetic SK pathogenesis
Following ocular HSV infection replicating virus could be detected in the cornea till 5-7 days p.i.
Early inflammatory response in the cornea is dominated by the polymorphonuclear leukocytes
(PMN). Infiltration of PMNs into the cornea is be characterized by a typical biphasic influx.
Angiogenesis or the process of new blood vessel development from the existing limbal vessels
starts at 24h p.i. and peaks around 15 days p.i. Influx of pathogenic CD4+ T lymphocytes occurs
in the clinical phase around 7-9 days p.i.
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PART-II
IN-VITRO GENERATED ANTIGEN-SPECIFIC
CD4+CD25+FOXP3+ REGULATORY T CELLS CONTROL
THE SEVERITY OF HERPES SIMPLEX VIRUS
INDUCED OCULAR IMMUNOINFLAMMATORY
LESIONS
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Research described in this chapter is a slightly modified version of an article that in accepted for
publication in Journal of Virology by Sharvan Sehrawat, Susmit Suvas, Pranita P Sarangi, Amol
Suryawanshi and Barry T Rouse

Sehrawat S, Suvas S, Sarangi PP, Suryawanshi A and Rouse BT. In vitro generated antigenspecific CD4+CD25+Foxp3+ regulatory T cells control the severity of HSV-induced ocular
immunoinflammatory lesions J Virol: 2008 : 82(14); 6838-6851. Copyright © 2008, American
Society for Microbiology.

In this chapter “our” and “we” refers to me and co-authors. My contribution in the paper includes
(1) Selection of the topic (2) Compiling and interpretation of the literature (3) Designing
experiments (4) understanding the literature and interpretation of the results (5) providing
comprehensible structure to the paper (6) Preparation of graphs and figures (7) Writing and
editing

Abstract
Generating and using regulatory T cells to modulate inflammatory disease represents a
valuable approach to therapy but not yet been applied as a means to control viral induced
immunopathological reactions. In this report we developed a simplified technique that used
unfractionated splenocytes as a precursor population and showed that stimulation under
optimized conditions for 5 days with solid phase anti-CD3 mAb in the presence of TGF-β and
IL-2 could induce up to 90% of CD4+ T cells to become Foxp3+ and able to mediate suppression
in vitro. CD11c+ DCs were intricately involved in the conversion process and once modified in
44

the presence of TGF-β could convert Foxp3-CD4+ cells into Foxp3+CD4+cells by producing
TGF-β. The converted cells had undergone cell division and the majority of them expressed
activation markers along with surface molecules that would facilitate their migration into tissue
sites. The primary reason for our study was to determine if such in vitro converted Tregs could
be used in vivo to influence the outcome of a virus induced immunoinflamatory lesion in the eye
caused by HSV infection. We could show in three separate models of herpetic stromal keratitis
(SK) that adoptive transfers of in vitro converted Treg effectively diminished lesion severity
especially when given in the initial phases of infection. The suppression effect in vivo appeared
to be polyspecific. The protocol we have developed could provide a useful additional approach
to control virus-induced inflammatory disease.

Introduction
Numerous types of regulatory T cells were reported to control the immune responses to
both self and foreign antigens (1). Impediments in regulatory T cell function can cause disease
conditions (2). The best known example is the multiple-organ autoimmune disorders that occur
in humans as well as in experimental animals when the gene for Foxp3 transcription factor is
mutated (3, 4). Functional inactivation of Foxp3 gene alters the development and
immunosuppressive activity of the natural regulatory CD4+ T cell population. In recent years,
naturally occurring Foxp3+ regulatory T cells were shown as the key cell type that maintains
peripheral tolerance (5). Additionally, these cells also regulate pathogen and allergen induced
inflammatory responses and boosting their functional activity may represent a valuable
therapeutic approach to blunt transplant rejection. Previously, it was reported that depletion of
nTregs prior to ocular infection with HSV-1, increased the severity of immunoinflammatory
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lesions in the cornea (6). However, it would be valuable to know if Tregs can modulate virus
induced ongoing immunoinflammatory reactions and influence the disease progression.
In this report, we took advantage of the recent observations that Foxp3+ T cells with
regulatory function can be generated from conventional T cells by appropriate in vitro activation
conditions (7-12). We modified the existing method to develop a simple in vitro technique to
generate Ova-specific Foxp3+ regulatory CD4+ T cells from CD4+Foxp3- cells. We then
determined the ability of in vitro generated Tregs to modulate the severity of an ocular
immunoinflammatory reaction caused by infection with Herpes simplex virus (HSV) in
conventional and bystander models of HSV-1 induced stromal keratitis. Our results showed that
adoptive transfer of in vitro generated Ova-specific Foxp3+ Tregs diminished lesion expression
in three different models of herpetic stromal keratitis (SK) in both an antigen-specific as well as
non-specific manner.

Materials and methods
Mice, Virus, cell lines
Female 6- to 8-wk-old BALB/c DO11.10 RAG2-/- mice were purchased from Taconic,
Thy1.2+ BALB/c and CB.17 SCID mice were purchased from Charles River and Thy1.1+
BALB/c mice were a kind gift from Dr. D. Woodland (Trudeau Institute, Saranac Lake, NY). All
animals were housed in the animal facilities at the University of Tennessee. BALB/c DO11.10
RAG2-/- and CB.17 SCID mice were kept in our specific pathogen-free facility where food,
water, bedding, and instruments were autoclaved and all manipulations were done in a laminar
flow hood. All experimental procedures were in complete agreement with the Association for
Research in Vision and Ophthalmology resolution on the use of animals in research. HSV-I RE
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Hendricks and HSV-I KOS was propagated and titrated on Vero cells (ATCC CCL81) using
standard protocols. The virus was stored in aliquots at -80°C until use.
Corneal HSV-1 infection and clinical observations
Corneal infections of un-manipulated BALB/c mice and DO11.10RAG2-/- animals and
adoptively transferred with iTregs were conducted under deep anesthesia. HSV RE and HSV
KOS were used for inducing keratitis lesions in immunocompetent BALB/c and DO11.10RAG2/- animals, respectively. Sometimes Tregs were adoptively transferred in previously infected
animals. Mice were scarified on their corneas with a 27-gauge needle, and a 3-µl drop containing
the required viral dose was applied to the eye. The eyes were examined on different days
postinfection (p.i.) with a slit-lamp biomicroscope (Kowa, Nagoya, Japan), and the clinical
severity of keratitis and angiogenesis of individually scored mice was recorded. The scoring
system was as follows: 0, normal eye; +1, mild corneal haze; +2, moderate corneal opacity or but
iris visible; +3, severe corneal opacity, iris invisible; +4, opaque cornea, ulcer formation; and +5,
necrotizing SK. The angiogenesis was scored as described previously (13).
Antibodies and reagents
CD4-APC (RM4-5), Thy1.1-PerCP (OX-7), DO11.10-PE (KJ1.26), CD25-FITC (7D4),
GITR-FITC (DTA-1), Folate Receptor 4-FITC (eBio12A5), CD62L-FITC (MEL-14), CD103FITC (M290), CD62L-APC (MEL-14) CD49d-PE (MFR4.B), ICAM-1-PE ( 3E2), ICOS-PE,
PDL-1-PE (MIH5), PD-1-FITC (J43), Foxp3-PE(FJK-16s), Foxp3-FITC (FJK-16s), CD69-FITC
(H1.2F3), CCR7-PE (4B12), CD11c-PE (HL3), anti-IFN- -FITC, anti-IL-10-FITC anti-IL-17PE were purchased from BD PharMingen (San Diego, CA). Recombinant human TGFβ-1, antiTGF β1,2,3 antibody (1D11) and anti IL-10 antibodies (AB-417-NA) were obtained from R&D.
anti-CD3 (145.2C11), anti-CD28 (37.51) were from BD Bioscience. Anti-PD1 antibody (J43)
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and anti-ICOS antibody (7E.17G9) were from ebioscience. Recobinant human IL-2 was obtained
from Hemagen. OVA323-339 peptide was obtained from Genscript. CFSE was obtained from
Molecular Probe and used at a final concentration of 0.5 µM for 15 min. at 370C in PBS.
In vitro generation of CD4+CD25+Foxp3+ regulatory T cells
Splenocytes isolated from DO11.10Rag2-/- mice were fractionated into CD4+ and CD4- T
cells using CD4+ T cell isolation kit. 1x106 of T depleted SPCs were pulsed with various doses
(2µM, 1µM, 0.62µM, 0.31µM and 0.15µM) of OVA peptide for 2 hours at 370C and washed
three times thereafter. Ova pulsed cells were then cocultured in 1:1 ratio with purified
CD4+CD25-Foxp3- cells in the presence of 10ng/ml of rTGF-β, and 25U of IL-2 for five days at
370C and thereafter the cells were characterized by Flow cytometry. To discount the possibility
of residual ova peptide transfer along with transferred Tregs for subsequent in vivo experiments,
Ova specific Tregs were also generated with plate-bound anti-CD3 mAb. To this end,
0.125µg/ml of anti-CD3 mAb in a volume of 200 µl was coated overnight in 48 well flat
bottomed plate in 0.1M Na2HPO4 buffer, pH 9.0. Before establishing culture of splenocytes with
the cocktail of various cytokines, plates were washed three times with medium after which
splenocytes were cultured as described above but in the absence of ova peptide.

Total

splenocytes were isolated from DO11.10RAG2-/- animals and red blood cells were lysed using
RBC lysing buffer. 2x106/ml of SPCs were cultured with various concentrations of recombinant
hTGF-β1 (5ng, 10ng or 15ng), IL-2 (100, 50, 25U) and anti-CD3 antibody in a checker board
fashion. The cultures were incubated for varying periods ranging from day 4 to day 7 at 370C in
a humidified CO2 incubator to find the optimum dose of all constituents in the cocktail and the
incubation periods that yielded a maximum percentage of induced Tregs. In certain experiments,
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splenocytes were cultured in 6 well culture plates to generate Tregs in bulk. The generated Tregs
were phenotypically characterized by flow cytometry.
Purification of cells
CD4+ and CD4- T cells were purified from naïve DO11.10 RAG2 -/- mice using CD4+ T
cells isolation kits (Miltenyi Biotec). In addition, CD4+ and CD4- T cells were also purified from
in vitro cultures for some in vivo experiments. CD11c+ DCs were isolated on magnetic beads
columns (Miltenyi Biotec) after 48 hours of in vitro cultures system either from those that
contained the culture medium that resulted in Foxp3+ T cell conversion or medium that lacked
TGF-β. CD4+CD25+ and CD4+CD25- T cells were isolated from in vitro cultures using CD4+
regulatory T cell isolation kit (Miltenyi Biotec). The depletion of T cells from splenocytes was
achieved by using Thy1.2 microbeads (Miltenyi Biotec). All purification procedures were
performed as per the manufacturers’ instruction.
In vitro suppression assay
In vitro suppression assays were performed to assess and compare the inhibitory activity
of iTregs and splenic nTregs against anti-CD3 stimulated CD4+CD25- T cells. To assess the
suppressive activity of iTregs, CD4+CD25+ T cells were purified from splenocytes cultured for 5
days in the presence or absence of recombinant TGF-β1. CD4+CD25- T cells were isolated from
pooled spleens and LNs of DO11.10RAG2-/- and labeled with 0.5µM of CFSE. T depleted
splenocytes were isolated from spleens of DO11.10RAG2-/- using Thy1.2 microbeads and
irradiated before use in the suppression assays. CFSE labeled CD4+CD25- T cells (5x104) were
cultured in the presence of soluble anti-CD3 mAb (1.0µg/ml) and irradiated splenocytes (1x105)
with sequentially diluted CD4+CD25+ T from either culture in 96-well round-bottomed plates.

49

After 72 hours, dilution of CFSE was analyzed by flow cytometry. The gate was applied on
CD4+CFSE+ T cells and the intensity of CFSE staining was analyzed.
To compare the suppressive activity of iTregs with splenic nTregs, iTregs were isolated
from the in vitro culture system and CD4+CD25+ cells isolated from the pooled spleens of
BALB/c animals. CD4+CD25- T cells isolated from pooled spleens and LNs of Thy1.1 BALB/c
animals and labeled with 0.5µM CFSE. Cultures were set up as described above and the dilution
of CFSE in Thy1.1+CD4+ gated cells was analyzed.
Measurement of in vivo activity of iTregs
Three different systems were used for measuring the in vivo activity of in vitro generated
Tregs. In the first series of experiments, cultured splenocytes containing 5x105 of
CD4+CD25+Foxp3+ T cells were adoptively transferred i.v. in DO11.10 RAG2-/- mice one day
prior or six days after ocular infection with 5x105 pfu of HSV I KOS and the lesion were scored
every alternate day beginning at day 4. At day 11, mice were sacrificed and cells recovered from
cornea, DLN and spleen were analysed by flow cytometry.
In the second set of experiments, 5x106 of isolated CD4+CD25- T cells from BALB/c
animals were transferred with or without 1x106 of either nTregs or OVA Tregs into SCID
animals which were then infected with ocular HSV I (5x105 pfu). The SK lesion progression and
angiogenesis was monitored for 12 days. To look for the proliferation of lesion orchestrating
CD4+ T cells, CFSE labeled CD4+CD25- T cells from BALB/c animals were transferred alone or
with iTregs or nTregs. These animals were infected 24hrs later with 5x105 pfu of HSV I (RE).
After 7 days of transfer, the proliferation of CD4+CFSE+ T cells was analyzed by dilution of
CFSE.
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Finally, experiments were done to look for the disease modulatory activity of Tregs in
immunocompetent BALB/c animals. Five different doses (2x106, 1x106, 5x105, 2x105 and 5x104)
of Foxp3+ T cells were adoptively transferred i.v. in BALB/c animals one day prior to the ocular
HSV RE (5x105 pfu) infection. The disease severity was recorded for 15 days post infection. A
minimum dose of Tregs which could inhibit the disease progression in these animals was used
for subsequent studies where cells were transferred one day before, three days or 6 days post
infection. Animals were sacrificed at different time intervals to collect and analyze lymphoid and
non-lymphoid tissues.
Flow cytometric analysis
Cell preparation Single-cell suspensions were prepared from the cornea, draining
cervical lymph nodes (DLN), and spleen of mice at different time points p.i. Corneas were
excised, pooled group wise and digested with 60 U/ml Liberase (Roche Diagnostics) for 60 min
at 37°C in a humidified atmosphere of 5% CO2 as described earlier (6). After incubation, the
corneas were disrupted by grinding with a syringe plunger on a cell strainer and a single-cell
suspension was made in complete RPMI 1640 medium.
Staining for flow cytometry The single-cell suspension obtained from LNs, spleen, and
corneal samples were stained for different cell surface molecules for FACS. All steps were
performed at 40C.Briefly, a total of 1 x 106 cells were first blocked with an unconjugated antiCD32/CD16 mAb for 30 min. in FACS buffer. After washing with FACS buffer, fluorochromelabeled respective Abs was added for 30 min. Finally, the cells were washed three times and
resuspended in 1% paraformaldehyde.
To enumerate the number of IFN-γ producing T cells, intracellular cytokine staining was
performed as previously described (26). In brief, 106 freshly isolated splenocytes and lymph node
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cells were cultured in U bottom 96-well plates. Cells were left untreated, stimulated with 2 MOI
of UV inactivated HSV I and incubated overnight at 37°C in 5% CO2. Brefeldin A (10 µg/ml)
was added for the last five hours of the culture period. After this period, cell surface staining was
performed, followed by intracellular cytokine staining using a Cytofix/Cytoperm kit (BD
PharMingen) in accordance with the manufacturer's recommendations. The Ab used was antiIFN-γ-FITC and anti-IL-17-PE. The fixed cells were resuspended in 1% paraformaldehyde and
acquired with BD FACSCalibur. The data were analyzed using the CellQuestPro 3.1 (BD
Biosciences) or Flowjo software.
BrDU incorporation assay
BrDU analysis was performed as described earlier (14). Briefly, mice were divided into
four groups: naïve, naïve + iTregs, infected and infected + iTregs. 5x105 iTregs were transferred
a day before ocular infection and animals were then fed BrDU in drinking water at 1mg/ml for
10 days after adoptive transfer of iTregs and ocular HSV 1 infection. After 10 days, host
CD4+Foxp3+ and CD4+Foxp3- cells that incorporated BrDU were analysed by staining with antiBrDU antibody using an APC BrDU flow kit from BD Pharmingen as per the manufacturers’
instructions.
Statistical analysis
To calculate the statistical significance for disease severity between different groups,
unpaired two-tailed Student's t test was performed. All other analyses for statistically significant
differences were performed with Student's t test. P ≤ 0.001 = *** P ≤ 0.01 = ** and P ≤ 0.05 = *
were considered significant. Results are expressed as mean ± SD. For some experiments, as
mentioned in the fig. legends, one way ANOVA test was applied.
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Results
In vitro Generation of Ova-specific Treg (iTregs)
In initial experiments, splenic cells from naive DO11.10 Rag2-/- animals were
fractionated on MACS columns into the T cell fraction (greater than 95% KJ+ CD4+ and hence
OVA-specific) as well as the non T cell fraction. These non-T cells were pulsed with various
concentrations of the OVA323-339 peptide and used to stimulate the T cell fraction in a 1:1 ratio.
The culture medium contained IL-2 (25U/ml) as well as human recombinant TGF-β (10ng/ml),
conditions expected to be suitable to induce Foxp3+ T cells from conventional precursors (7, 10).
Using these conditions, we observed that after a 5 day culture period up to 70% (range 50-70%)
of the surviving cells in the culture were Foxp3+. The dose of ova peptide that gave maximum
conversion efficiency was 0.31μM.
To simplify matters, we also cultured unfractionated DO11.10 Rag2-/- naive splenocytes
in culture plates that had been pre-incubated with various concentrations of rat anti-mouse CD3
antibody. In preliminary experiments using 0.3μg/ml to sensitize plates and the same TGF-β and
IL-2 concentrations described above, up to 75% ( range 70-75%) of cells were observed to be
Foxp3+ after 5 days stimulation (Fig. 2.1A). When peptide (0.31μM) was used for stimulation
instead of anti-CD3, up to 45% (range 30-45%) of CD4+ T cells became Foxp3 (data not shown).
Subsequently, the system was optimized by using varying concentrations of anti-CD3 and TGFβ, but using the same amount of IL-2. As shown in figure 2.1B and C, a concentration of
0.125μg/ml of anti-CD3 and 10 ng/ml of TGF-β turned out to be optimal. With the optimal
conditions, the frequency of CD4+ T cells that were Foxp3+ ranged from 80% to 90% of the
CD4+ T cells in different experiments (Fig. 2.1D). These conditions were chosen for subsequent
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experiments in which in vitro converted cells were used in vivo in an attempt to modulate HSV
induced ocular inflammatory lesions.

During the conversion process, the Foxp3+ T cells

underwent division (one to six times) although some converted cells must have died since the
overall yield of Foxp3+ cells was usually around two fold the number of input Foxp3-CD4+ T
cells (Fig 2.1E).
Phenotypic Characterization of iTregs
Using optimal Foxp3 conversion conditions, cultures were terminated at various times
after initiation not only to establish the time when conversion was at its maximum, but also to
measure the expression of additional phenotypes on the Foxp3+ T cells that could play a role in
their migratory and functional properties in vivo. The results are expressed in fig 2.2A. Maximal
frequencies of Foxp3 expression were evident after 5 days and these frequencies sometimes
exceeded 90% of the surviving CD4+ T cells.
As shown in fig. 2.2B, most of the Foxp3+ T cells at the end of the culture period were
CD103+, a molecule important for migration into tissue sites (15). This, as well as some other
markers, was present on only a minor population of the CD4+Foxp3+ nTreg population isolated
from spleens of naïve immunocompetant mice (Fig 2.2B). Additional phenotypic markers
present on the majority of the in vitro converted Foxp3+ T cells at the end of the culture period
included CD25, GITR, folate receptor 4 (FR4), PD1, ICOS, ICAM-1, CD62L, CD49d, CCR7
and CCR5. Their higher level (mean fluorescence intensity and percent positive) of expression
on the in vitro converted Tregs compared to nTregs indicated that the in vitro converted cells
were in a more activated state and more endowed with surface molecules that would permit
tissue migration (Fig 2.2B and 2C).
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TGF-β modified CD103+CD11c+ DCs are involved in Foxp3 induction
It was of interest to note that the expression of some phenotypic markers observed at the
end of the culture period was not evident on those Foxp3+ cells that had been converted early
during culture. The striking example of this was CD103, a molecule involved in tissue homing in
vivo (15). Curiously after two days of culture, the majority of CD11c+ dendritic cells (DCs) were
already CD103+ but only a minor fraction (up to 2-5%) of CD4+Foxp3+ was CD103+ (Fig 2.3A
and B). The dendritic cells isolated from cultures lacking TGF-β, after two days, did not show
this phenotype. We suspected that the CD103+ DCs could be the cells that were mainly
responsible for causing the majority of CD4+Foxp3+ conversion observed in our culture system.
In support of this notion, we could demonstrate that the DCs isolated from cultures after two
days, could be used to drive Foxp3 expression in de novo cultures of purified CD4+CD25-Foxp3T cells that were TCR stimulated in the presence of IL-2, but without additional TGF-β in the
culture system. Accordingly, CD11c+ cells were isolated by positive selection from 2 day
stimulated splenocytes with anti-CD3, IL-2 and TGF-β (conversion medium). In addition,
CD11c+ cells were isolated from similar cultures that lacked TGF-β. The purity of CD11c+ DCs
was between 85 to 90% in different experiments.
As shown in Fig.2.3C, the addition of CD11c+ cells from cultures with the conversion
medium caused up to 50% of CD4+ cells to become Foxp3+ after 4 days further stimulation in the
absence of TGF-β. In contrast, CD11c+ cells from the two day culture that lacked TGF-β failed
to induce significant numbers of Foxp3+ converted cells in the secondary cultures. We interpret
these experiments to mean that the CD11c+ cells were intricately involved in the in vitro
conversion process perhaps by being modified in their function during the initial culture period.
This modification could include acting as a source of TGF-β. Thus, the addition of anti-TGF-β
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antibody either in primary or secondary cultures markedly inhibited the induction of Foxp3 in
purified Foxp3-CD25-CD4+ (Fig 2.3C). Furthermore, the DCs isolated after two days in the
conversion system had higher TGF-β mRNA levels than did DCs stimulated under non
converting conditions (data not shown).
Functional activity of Foxp3 converted cells
At the end of the 5 days culture period, CD25+CD4+ T cells were isolated from both
cultures stimulated with the conversion medium as well as cultures that were stimulated in the
presence of IL-2 but without TGF-β. These cultures without TGF-β failed to generate significant
numbers of Foxp3+CD4+ T cells as already stated. Both sets of CD25+ cells were added to antiCD3 stimulated naïve CD4+CD25- OVA-specific T cells isolated from pooled spleens and LNs
of DO11.10Rag2-/- mice and irradiated T depleted splenocytes from the same strain of mice, to
measure their anti-proliferation activity. As shown in Fig. 2.4A, only the Foxp3+ containing
population showed a dose dependent suppressive activity. Experiments were also performed to
determine possible mechanisms involved in the suppressive activity of iTregs. Neutralizing
antibodies to either TGF-β, IL-10, ICOS or PD-1 were added in suppression assays. The
suppressive activity was only diminished significantly when PD-1 blocking antibody was added
to the cultures (Fig. 2.4B. We interpret these experiments to mean that the suppression did not
involve either TGF-β or IL-10 cytokines and that PD-1 engagement was likely involved in the
suppression mechanism as previously observed by others (16).
In a second approach, CD25+CD4+ T cells from in vitro conversion cultures and splenic
CD25+CD4+ nTregs isolated from immunocompetant BALB/c animals were compared for their
ability to suppress the proliferation of CD25-CD4+ T cells. The latter were isolated from pooled
spleens and LNs of naïve Thy1.1 BALB/c animals (hence polyspecific population) stimulated
56

with anti-CD3 antibody and T depleted irradiated splenocytes as a source of APCs. Proliferation
of Thy1.1+CD4+ T cells was analyzed by dilution of CFSE. In such experiments, the Ovaspecific converted cells showed activity that was somewhat enhanced compared to the nTreg
population (Fig 2.4C).
In vivo activity of in vitro converted cells in ocularly infected DO11.10RAG2-/- mice
The major objective of our investigation was to determine if in vitro converted
Foxp3+cells could influence the severity of ocular immunoinflammatory lesions induced in mice
by HSV infection. The first model used TCR transgenic mice on a RAG-/- background which
were shown previously to develop stromal keratitis (SK) upon ocular infection with HSV even
though their CD4+ T cells were almost all reactive with OVA323-339 peptide and not detectably
cross-reactive with HSV antigens (17).The T Cells in the ocular lesions of such animals were
shown to react with the KJ1-26 monoclonal antibody noted by others to react with the TCR of H2d CD4+ T cells that recognize the OVA323-339 peptide (18). Since this KJ+ TCR had no
demonstrable reactivity with HSV, we surmised that the activation of KJ+CD4+ T cells was not
TCR mediated but involved activation by one or more cytokines (19). We have referred to this
as a bystander model of SK (11).
As already described the Foxp3 converted cells in the in vitro system used in this
communication were all KJ+ and hence OVA-specific. Consequently, we speculated that such
cells adoptively transferred into the infected DO11.10RAG2-/- animals should modulate the
severity of the ocular lesions. To test this, DO11.10 RAG2-/- mice were ocularly infected with
5x105 pfu of HSV KOS (which routinely induces SK in these animals) and some were given
intravenously 5x105 Foxp3 converted cells either 24hrs before or at 6 day p.i. The severity of
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lesions was then followed in control and adoptive transfer recipients over a 11-12 day
observation period (animals began to die after day 11 from herpetic encephalitis).
The cumulative results of three similar experiments are shown in Fig 2.5A, and B. As is
evident, the average severity of ocular lesions was significantly reduced in animals that received
cells 24 hours before infection. Similarly, lesion severity was also reduced significantly in the
day 6 recipients. Samples were collected from both groups of animals to determine if the
adoptively transferred Foxp3+ T cells could be demonstrated in the recipient tissues. It became
possible to detect transferred cells since the DO11.10 RAG2-/- animals do not have detectable
Foxp3+ cells even following infection with HSV. The results of such experiments revealed that
both in day-1 and day -6 transfer recipients, appreciable numbers of Foxp3+ cells could be
demonstrated by FACS analysis of collagenase digested ocular samples as well as in the draining
LN and spleen (Fig 2.5C). Reduced percentages as well as absolute numbers of PMNs such as
neutrophils (CD11b+Gr1+) were found in the corneal tissues of transfer recipients as compared to
control animals (Fig 2.5D).These experiments clearly demonstrated that the in vitro Foxp3
converted cells may function in vivo to diminish herpetic lesions although in the model studied
we could not establish how the inhibition was achieved or if this occurred by the action of
Foxp3+ cells in the ocular tissue themselves or in the DLN in some way. It remains unclear how
HSV infection causes SK in the DO11.10RAG2-/- model but we suspect the mechanism involves
the activation of CD4+ T cells by inflammatory mediators generated by the infection. In support
of this, CD4+ T cells collected from lymphoid tissues as well as cornea showed high frequencies
of CD69+ cells indicating they are activated. Transfer of iTregs into such animals significantly
reduced the frequencies of activated cells (data not shown).

58

Inhibitory effects of Treg on SK in reconstituted SCID mice
Whereas SCID animals ocularly infected with HSV fail to develop SK lesions, they do so
if reconstituted with CD4+CD25- T cells even if such cells are taken from naïve animals (6). In a
previous study, we demonstrated that SK severity in such animals was inhibited if CD4+CD25+ T
cells were cotransferred with the CD4+CD25- population. As shown in Fig. 2.6A, this
observation was repeated but in addition we were able to show that Ova-specific iTregs were
equally capable of modulating lesion severity. This occurred despite the fact the iTregs
population was KJ+ and hence ova-specific. Such experiments indicate that iTregs may act in a
bystander inhibitory fashion but how such an effect was mediated requires further exploration.
The effect appeared to involve inhibition of proliferation of effectors. This was shown in
experiments wherein CFSE labeled CD4+CD25- (effectors) cells were transferred alone or with
either iTregs or nTregs in SCID animals 24 hrs before ocular HSV I infection. As shown in Fig.
2.6B, the frequencies of proliferating cells, when measured at day 7 p.i., were reduced in
recipients of both iTregs and nTregs as indicated by dilution of CFSE.
Inhibition of SK by iTregs in immunocompetent BALB/c animals
The final approach used to measure the efficacy of in vitro converted Foxp3+ T cells was
to use the immunocompetent ocularly infected BALB/c animals as the transfer recipients. In
these experiments, animals were infected with 5x105 pfu of HSV RE, a dose which was expected
to cause lesions in the majority of recipients and the outcome was compared in control animals
with those given different numbers of in vitro converted cells day-1 prior to infection. The
numbers of donor cells varied from 2x106 to 5x104 of Foxp3+ T cells which it must be
emphasized were KJ+ and hence Ova-specific. The results of a representative experiment are
shown in Fig 2.7A. As can be seen, lesions were markedly reduced in recipients given 2x106
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donor cells but inhibition was also significant in those that received 5 fold less cells. Using the
5x105 donor cell dose for transfer, we also compared the suppressive effects of donor cells that
were fractionated into CD4+ and CD4- populations prior to transfer. As is evident in Fig 2.7B,
only the CD4+ fraction suppressed lesion severity in the BALB/c recipient animals.
In subsequent experiments, HSV infected BALB/c animals were given adoptive transfers
of Foxp3+ converted cells (5x105 Foxp3+ cells) either one day before, or 3 or 6 days p.i. Animals
were then scored for both the extent of angiogenesis and SK lesion severity scores over a 15 day
observation period. The data in Fig 2.7C and D, show the cumulative data of individual animal
scores of three separate experiments. As is evident, significant levels of inhibition occurred in the
early transfer recipients. Transfers at day 6 provided suppression in some animals but overall the
results were not significant especially at day 15 p.i. probably because of lower sample size and
large variations. Interestingly, transfer of Tregs at day 3 invariably failed to produce suppression
of SK or levels of angiogenesis. This might be explained by the fact that levels of
proinflammatory cytokines, such as IL-6 are high at this time in the DLN and cornea (Fig 2.7E)
Thus cytokines such as IL-6 are known to blunt the function of Tregs (20). Inhibition could be
achieved in the day 3 transfer model if ten fold more cells were transferred on day 3 (Fig 2.7F
and G). Conceivably, the inhibition was evident because insufficient IL-6 was present to blunt
the function of all of the transferred Tregs, but this issue needs to be formally explained.
Our data demonstrate that early transfer of Foxp3 converted OVA-specific T cells are
fully capable of inhibiting lesions caused by HSV provided sufficient cells are transferred and if
performed early after infection. It is far from clear how the Treg which are OVA-specific, act
against an inflammatory lesion caused by HSV or in fact where the inhibitory effect is mediated.
Experiments showed that adoptively transferred cells (based on determining the KJ+ markers)
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could be demonstrated to be present at least in appreciable numbers in the eye as well as
lymphoid tissues at 16 day post transfer (Fig 2.8A). In long term studies, transferred cells (2-3%
of recovered CD4+ T cells) could be found in corneal tissues even after three month post transfer
but such cells were undetectable in lymphoid tissues at this time point (data not shown). It
would be interesting to investigate if corneal resident iTregs could prevent the recurrence of
stromal keratitis.
Although some adoptively transferred iTregs could be demonstrated in ocular tissues,
their polyspecific suppressive activity could be mediated mainly in lymphoid tissues. Thus, one
consequence of HSV infection is an increase in the spleen size as well as the DLN. Curiously, as
shown in the Fig. 2.8B and C, the spleen size and total cellularity in iTreg recipients was reduced
approaching near to that of normal animals depending on the number of iTregs given. In
addition, iTregs recipients showed lower numbers of HSV-specific IFN-γ producing CD4+ T
cells (Fig 2.8D), those principally responsible for mediating SK (21) than was evident in control
infected animals that did not receive iTregs. Accordingly one outcome of the early iTreg transfer
was suppression of the response of CD4+ T cells to HSV although how this was achieved
mechanistically remains to be explained. Regulatory cells transferred at day 6 had no effect on
the magnitude of the anti-HSV immune response (data not shown).
We considered the possibility that iTreg adoptive transfers might serve to inhibit the
division of host effectors while at the same time causing the expansion of the hosts’ own nTregs
as was reported in a diabetes model by the Steinman group (22). To support such a possibility,
we performed adoptive transfers with KJ+Treg and then compared the proliferative capacity of
the host’s CD4+Foxp3+ and Foxp3- populations. Our results showed reduced proliferative
responses of host CD4+Foxp3- cells compared to infected controls not given iTregs, but an
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increase in the proliferative response of the host CD4+Foxp3+ population. Thus, the donor
KJ+Tregs appeared to mediate the suppression in at least two ways. These included inhibitory
effects on the host effectors as well as an expansion of the host’s own nTregs population.
Curiously, the donor KJ+ cells themselves underwent proliferation in the host which may also
help explain how the minimal cell transfers were effective at modulating lesions.

Discussion
In this report we have confirmed the observations of others that Foxp3+ regulatory T cells
can be generated in vitro from Foxp3- naïve CD4+ cells (7, 10). We developed a simplified
technique that used unfractionated splenocytes as a precursor population and showed that
stimulation under optimized conditions for 5 days with solid phase anti-CD3 mAb in the
presence of TGF-β and IL-2 could induce up to 90% of CD4+ T cells to become Foxp3+ and able
to mediate suppression in vitro. The converted cells had undergone cell division and the majority
of them expressed activation markers along with surface molecules that would facilitate their
migration into tissue sites. The primary reason for our study was to determine if such in vitro
converted Tregs could be used in vivo to influence the outcome of a virus induced
immunoinflammatory lesion in the eye caused by HSV infection. We could show in 3 separate
models of herpetic stromal keratitis (SK) that adoptive transfers of in vitro converted Treg
effectively diminished lesion severity especially when given in the initial phases of infection.
The protocol we have developed, which is novel for a viral induced inflammatory disease, could
provide a useful additional approach to control a chronic virus induced lesion.
Previous studies on adoptive transfers with in vitro converted Tregs have focused on the
control of autoimmune lesions or to facilitate the acceptance of transplants (23-27). Moreover,
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the techniques used to produce the Treg populations were usually complex requiring purification
of both responders and stimulators to achieve success. We have found that unfractionated
splenocytes can suffice as a responder population. In our case, these were transgenic T cells from
naïve DO11.10 RAG2-/- mice which normally lack a population of Foxp3+ T cells (28). The T
cells from such animals are predominantly CD4+ and express a TCR that recognizes the ova
peptide that can be conveniently identified with the KJ26 monoclonal antibody. We could
generate Foxp3+KJ+ cells either by stimulating splenocytes with ova peptide in the presence of
TGF-β and IL-2, or more effectively by stimulating with solid phase anti-CD3 mAb. It was not
necessary to use additional costimulators such as anti-CD28 as is used in most other studies (7,
10, 29). The Foxp3 conversion process involved cell division and appeared to depend on the
presence of APC that responded initially to the TGF-β. Thus, we could show that 2 day
stimulation of splenocytes in the conversion medium caused CD11c+ cells in the culture to
become CD103+. Moreover, such cells could be used to drive Foxp3 expression in TCR
stimulated cultures of naive CD4+Foxp3- T cells without the addition of TGF-β to cultures. We
interpret these observations to mean that the CD103+CD11c+cells could be a source of TGF-β
and possibly costimulation to the CD4+ cells that convert to become Foxp3+. Curiously, recent
studies on Foxp3 conversion in the gut had demonstrated an essential role of CD103+ TGF-β
producing dendritic cells (30-34).
The principal objective of our studies was to explore the value of adoptive transfers with
regulatory T cells as a means to influence the pathogenesis of a viral induced
immunoinflamatory lesion. In prior studies, we had shown that lesions caused by HSV infection
in the eye were more severe in animals depleted of nTregs (6) so it was anticipated that adoptive
transfers of Tregs might prove valuable to suppress the severity of SK lesions. However, as is
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well known when using Treg therapeutically to control autoimmunity, the most potent Treg
populations are those that are reactive with the same antigens as the effectors cells that drive the
lesions (22, 23, 25). Unfortunately, we have no simple means of generating HSV-specific Tregs
in vitro although this issue is under further investigation. There is, however, an SK model using
TCR transgenic x Rag or SCID mice where the animals’ T cells lack demonstrable crossreactivity with HSV (17). Nonetheless, they develop stromal inflammatory lesions upon ocular
infection with HSV. This has been referred to as the bystander model of SK (19). Using this
model we could show that the adoptive transfer of in vitro generated Foxp3+KJ+ T cells could
inhibit the severity of SK in HSV infected DO11.10RAG2-/- mice wherein

lesions are

orchestrated by CD4+ effectors that are also KJ+ (19). In this instance therefore, the Treg control
could be antigen-specific.
Inhibition was most effective when the Tregs were given around the time of infection but
significant effects were also evident in animals in which therapy was delayed until day 6. We
consider this latter observation particularly interesting since it indicates that the adoptive transfer
of Treg may represent a potential means of controlling ongoing viral inflammatory disease. We
suspect that even greater efficacy in the day 6 therapeutic model could be observed if animals
were kept alive for longer than the usual time of their dying of herpetic encephalitis (around day
11). We are currently pursuing such experiments in animals treated with anti-virals or protected
by neutralizing antibody. In longer living animals multiple Treg administration will also be
feasible, perhaps a necessary protocol to fully control lesions.
Unexpectedly, we were also able to show that in vitro generated Ova-specific Foxp3+
Tregs could modulate lesions in HSV infected BALB/c mice where certainly the CD4+ T cells
involved in orchestrating lesions were not KJ+ and ova specific. Such observations could mean
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that adoptively transferred Tregs can act non-specifically. This could be possible since the cells
used for adoptive transfer were highly activated and in fact showed enhanced regulatory effects
in vitro compared to nTregs isolated from normal animals. In fact if the iTregs were transferred a
week or more in animals prior to infection, control was not achieved (data not shown). During
this time we presume that cells may have lost their activation status although this issue needs to
be investigated.
Evidence for a non-specific regulatory effect of the in vitro converted Tregs was also
seen in a second model of SK. In this model, SK can be induced in ocularly infected SCID mice
as long as they are provided with adoptive transfers of normal or HSV immune CD4+ T cells (6).
We could demonstrate that co-transfer of the Ova-specific converted Tregs along with the
polyspecific CD4+ CD25- T cells resulted in significantly reduced lesions. These results provide
evidence of non-specific bystander regulatory effects since the lesion-inducing effector cells
would not be reactive to Ova peptide. Others too, have reported instances where Tregs could
mediate bystander suppression (35-37). This is especially evident for regulatory cells that are
abundant producers of cytokines such as IL-10 (26). However, we suspect that the bystander
suppression effect in our system may not involve IL-10 because only a minor fraction of the cells
could be shown to be IL-10 producers and the suppressive activity in vitro was found largely
independent of cytokines. Nevertheless, this issue requires further investigation.
Although our results demonstrate that in vitro converted Tregs could suppress the
severity of SK lesions, the location and mechanism by which the inhibition occurs in vivo
remains unclear. Thus, the cell population expressed several molecules that permitted the cells to
access tissue sites as well as lymphoid tissue. In fact, adoptively transferred cells could be
demonstrated at both the ocular inflammatory site as well as in lymphoid tissues. Some reports
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advocate that TGF-β generated Foxp3+ cells have only a short life span in vivo (26, 38). This was
not our experience since some KJ+Foxp3+ cells could still be recovered from the eyes of BALB/c
mice three months after their administration. Finding cells in the eye does not mean that they
exert their regulatory effect in that tissue. In fact, we strongly suspect that the suppressive effects
of the early cell transfers were mediated mainly in lymphoid tissues where the effector T cell
response to the virus is being generated. Thus recipients of such transfers had reduced HSVspecific effector CD4+ T cell responses. Moreover, few if any effector T cells appear in the
stroma until 6 or 7 days post infection (39).
Another interesting observation was that the viral-induced immunopathology was
suppressed by quite small numbers of adoptively transferred iTregs. Conceivably, the iTregs
could in some way be causing the host’s own nTregs to become activated and suppressive as has
been suggested to occur with similar studies in a diabetes model (22). In this model, control of
pancreatic inflammation appeared to be mediated by the increased population of host derived
Tregs in the tissue. In fact, donor cells were not demonstrable in the recipient tissues. In our
system we, could demonstrate the presence of transferred cells in the target tissues but, in
addition we noted that host nTregs underwent increased proliferation in iTreg adoptive transfer
recipients compared to controls. Such host nTregs could conceivably contribute to the
suppression of lesions as ongoing studies are attempting to demonstrate.
Finally, although the results were variable we could demonstrate that even in the BALB/c
model that transfer of Tregs at 6 days p.i., around the time of major access of effector T cells into
the corneal stroma, could suppress lesion severity. Transfer of Treg at this time period had no
effect on the magnitude of the anti HSV immune response which is approaching its peak at this
time. Conceivably the suppressive activity of such transfers could result from effects in the
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tissues themselves. It may be that multiple transfers would be a more effective way of controlling
ongoing lesions as we are currently investigating.
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Figure 2. 1 In vitro generation of Foxp3+CD4+ T cells from OVA-specific precursor Foxp3CD4+ T cells.
A. Splenocytes from DO11.10RAG2-/- mice were cultured in the presence of 0.3μg/ml of antiCD3 antibody, 25U of rIL-2 and the indicated concentrations of TGF-β. More than 99 percent of
CD4+ T cells were KJ1-26 positive (gated on CD4+ T cells). After five days of culture, cells were
analyzed for the expression of CD4 and Foxp3. Using these conditions approx. 75% of CD4+ T
cells became Foxp3+.
B. Dose response curve for Foxp3 induction with various conc. of anti-CD3 antibody, 10ng/ml
of TGF-β and 25U of IL-2 is shown. A dose of 0.125μg/ml of anti-CD3 antibody (plate bound)
was found to be optimal.
C. Dose response histogram for Foxp3 induction with various conc. of TGF-β, 25U of IL-2 and
0.125μg/ml of anti-CD3 is shown. At a dose of 10ng/ml of TGF-β 80 to 90 % of CD4+ T cells
converted to become Foxp3+.
D. Representative histograms for gated CD4+ T cells are shown to show the Foxp3 induction
using optimal conditions (0.125μg/ml of plate bound anti-CD3 antibody, 25U of IL-2, 10ng/ml
of TGF-β).
E. Splenocytes from DO11.10RAG2-/- animals were CFSE labeled and cultured with plate
bound anti-CD3, IL-2 and TGF-β for five days. After five days cells were stained with CD4 and
Foxp3. CFSE dilution and Foxp3 expression was shown in gated CD4+ T cells. TGF-β induced
CD4+CD25+Foxp3+ T cells proliferate extensively.
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Figure 2. 2 Phenotypic characterization of in vitro generated Foxp3+ T cells.
A. Representative FACS plots out of three similar experiments are shown for the kinetic analysis
of Foxp3 induction in CD4+CD25-Foxp3- T cells in in vitro cultures. Maximum conversion was
observed at day 5 after initiation of culture. (Gated on CD4+ T cells). B. Expression of surface
markers on in vitro converted Foxp3+ cells was compared with that of nTregs isolated from
spleens of naïve immunocompetent animals. Representative histograms are shown. (CD4+Foxp3+
T cells were gated, doted lines represent isotype control, solid lines represent expression on
nTregs and solid but bold lines represent expression on iTregs). C. Bar diagram of percent
positive of Foxp3+ nTregs and iTregs for various surface markers is shown.
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Figure 2. 3 Splenic CD11c+ DCs are intricately involved in causing conversion of Foxp3- T
cells into Foxp3+ CD4+ T cells.
Kinetics of CD103 expression on CD4+Foxp3+ T cells (A) and CD11c+ DCs (B) in in vitro
conversion culture is shown. The expression of CD103 was observed earlier on DCs than on
CD4+Foxp3+T cells. C. CD11c+ DCs were purified from 48hr splenocyte cultures in presence of
anti-CD3, IL-2 and either without TGF-β as used in (C(a)) or with TGF-β as used in (C(b) and
(C(d)) or with TGF-β + anti-TGF-β as used in (C(c)). These DCs were then co-cultured in 1:5
ratios with anti-CD3 stimulated purified CD4+CD25-Foxp3- T cells isolated from naïve
DO11.10RAG2-/- animals in presence of IL-2 alone or with anti-TGF-β antibody.
Representative FACS plot showing Foxp3 induction when the DCs were isolated from primary
culture with no TGF-β (C(a)), primary culture in presence of TGF-β (C(b)), primary cultures in
presence of TGF-β and anti-TGF-β and when DCs were from primary culture with TGF-β but
anti-TGF-β antibody was added in secondary cultures.
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Figure 2. 4 In vitro generated Tregs inhibit the proliferation of antigen-specific and
polyspecific CD4+CD25- T cells.
CD25+CD4+ T cells were isolated from both cultures stimulated with the conversion medium
(Tregs) as well as cultures that were stimulated in the presence of IL-2 only (“control cells”).
Additionally, CD4+CD25+ T cells were also isolated from pooled spleens and LNs of BALB/c
animals. These cells, in two fold serial dilutions, were used in suppression assays against the
cultures of anti-CD3 antibody stimulated CFSE labeled CD4+CD25-T (1x105) cells from naïve
DO11.10RAG2-/- (i.e. to measure antigen-specific effect) and Thy1.1 BALB/c animals (i.e. to
measure polyspecific effect) with irradiated T depleted splenocytes (2x105) from homologous
system as described in Material and Methods section.
A. The extent of CFSE dilution as an indication of suppressive activity of in vitro generated
CD4+CD25+ regulatory T cells against anti-CD3 stimulated labeled CD4+CD25- T cells from
naïve DO.11.10 RAG2-/- animals is shown. Of the CD4+CD25+ T cells, about 90% and 3% were
Foxp3+ from cultures in the presence or absence of TGF-β, respectively. A first gate was applied
on CD4+ T cells and then extent of CFSE dilution in CD4+CFSE+ T cells was analyzed.
B. Blocking antibodies to either TGF-β (10μg/ml) or IL-10 (10μg/ml) or PD-1 (10μg/ml), or
ICOS (10μg/ml) were added to the suppression cultures and the extent of division of CFSE in
labeled cells was determined. Representative FACS plots at two dilutions of Tregs to Teffectors
are shown for PD-1 and ICOS neutralized cultures. Dashed line represents dilution of CFSE
when no Tregs were added, solid line represents dilution of CFSE when Tregs were added, solid
but bold line represents dilution of CFSE when along with Tregs either anti-PD1 or anti-ICOS
antibodies were added.
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C. Representative histograms indicating CFSE dilution in the Thy1.1 gated population is shown.
CD4+CD25+ T cells were isolated from iTreg culture, control cells and splenic nTregs from
BALB/c animals and were used against anti-CD3 stimulated labeled CD4+CD25- T cells from
Thy1.1 animals. The markers show the percentages of cells that underwent less than two
divisions.
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Figure 2. 5 In vitro generated OVA Tregs control SK severity in a bystander disease model.
5x105 Foxp3+CD4+ T cells were adoptively transferred to DO11.10 RAG2-/- animals 24 hours
before or 6 days post ocular HSV I infection. The disease severity and angiogenesis was
recorded.
A. Gross eye pictures of control and transfer recipient animals from a representative experiment
when 5x105 Foxp3+ cells were transferred 24 hours before infection are shown.
B. Cumulative data on SK severity and angiogenesis from different experiments at 11 days p.i. is
shown. 5x105 Foxp3+ T cells were transferred 24 hours before or 6 days post infection. P values
were calculated with one way ANOVA using a Dunnet post test settings.
C. Distribution of adoptively transferred Foxp3+ T cells in lymphoid organs (spleen and draining
cervical LN) and ocular tissues at 11 dpi is shown.
D. Representative FACS plots showing the infiltration of neutrophils (CD11b+Gr1+) in
collegenase digested cornea from control and transfer recipient animals given 5x105 Foxp3+ cells
were transferred 24 hours before infection are shown. Absolute numbers of neutrophils/cornea
are shown in parenthesis.
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Figure 2. 6 Co-transfer of in vitro generated Tregs with polyspecific CD4+CD25- T cells in
SCID animals reduces the severity of SK.
1x106 CD4+CD25+ T cells isolated from in vitro cultures and splenic nTregs (CD4+CD25+ T
cells) from naïve BALB/c animals were co transferred with 5x106 CD4+CD25- T cells 24 hours
before ocular HSV I infection (5x105 pfu). The disease severity and angiogenesis was recorded
over a 12 days period.
A. The SK lesion scores and angiogenesis at 12 days p.i. are shown.
B. Proliferation of polyspecific CFSE labeled CD4+CD25- T cells in spleen and DLN in the
presence iTregs or splenic nTregs is shown.
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Figure 2. 7 In vitro generated OVA-specific Tregs diminishes the severity of SK in
immunocompetent BALB/c transfer recipients in a dose dependent manner.
A. Indicated doses of unfractionated Foxp3+ T cells were adoptively transferred in BALB/c
animals 24 hours before ocular HSV infection and the disease severity was monitored until day
15. A bar diagram indicating the average SK lesion scores at different doses of transferred
Foxp3+ cells at 15 days p.i. is shown. P values were calculated with one way ANOVA using a
Dunnet post test settings taking no Tregs as a control. B. 5x105 of fractionated CD4+ and nonCD4+ cells isolated from in vitro conversion cultures were transferred in BALB/c animals.
Average lesion scores is shown at 15 days p.i. Only CD4+ T cells could control the severity of
SK. Student’s t test (unpaired) was used for calculating the level of significance
C. 5x105 Foxp3+ cells were transferred 24 hours before, 3 days or 6 days p.i. and SK severity
was recorded. Lesion scores and angiogenesis is shown at 10 days p.i. and 15 days p.i. No SK
modulatory activity was shown by Tregs at 3 dpi transfer. P values were calculated with one way
ANOVA using a Dunnet post test settings.
D. Eye pictures of control and iTregs transfer recipient animals from a representative experiment
when 5x105 and 1x106 Foxp3+ cells were transferred 24 hours before infection are shown. E.
The kinetics of the levels of proinflammatory cytokine IL-6 in cornea and DLN after ocular HSV
I infection as determined by sandwich ELISA is shown. F-G. Indicated doses of iTregs were
transferred at 3dpi in BALb/c animals and lesion severity

(F) and angiogenesis (F) were

recorded at day 15 and compared with one way ANOVA using a Dunnet post test settings.
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Figure 2. 8 Adoptively transferred Foxp3+KJ1.26+T cells were present in lymphoid and
ocular tissues and diminished HSV-specific CD4+ T cell immune response.
BALB/c animals were given 5x105 of iTregs before 24 hrs or 3 days or 6 days p.i. of ocular
HSV infection and 15 days pi DLNs, spleens and ocular tissues were examined for the presence
of CD+Foxp3+ and KJ+ T cells. A. Representative FACS plots are shown. B-D. BALB/c animals
were given indicated numbers of iTregs before 24 hrs of ocular HSV infection and 15 days pi
immune parameters were studied B. Spleen size as an indication of generated immune response
is shown in control and iTreg recipient animals. C. Total cellularity in the spleen (blank bars) and
DLN (filled bars) of controls and Treg recipient animals is shown. D. Total number of IFNγ+CD4+ T cells in Spleen and LN of control and Treg recipients is shown. E-F. 5x105 iTregs
were transferred into 12 animals which were then divided into four groups: naive, naïve + iTregs,
Infected and Infected + iTregs. Animals in Naïve + iTregs and Infected + iTregs were given
5x105 iTregs. After 24 hrs, animals from Infected and Infected + iTregs were infected with HSV
1. All animals were given BrDU in DW for next 10 days. After 10 days spleens and draining
cervical LNs were analyzed for the frequencies of host CD4+Foxp3+ or CD4+Foxp3- and donor
CD4+KJ1-26+Foxp3+ cells that incorporated BrDU. Representative FACS plots for host cells (E)
and donor cells (F) are shown.

88

89

PART-III
ANTI-INFLAMMATORY EFFECTS OF FTY720
AGAINST VIRAL INDUCED IMMUNOPATHOLOGY:
ROLE OF DRUG INDUCED CONVERSION OF T CELLS
TO BECOME FOXP3+ REGULATORS
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This chapter is a slight modification of the research paper published in 2008 in The Journal of
immunology by Sharvan Sehrawat and Barry T Rouse.

Sehrawat, S and B. T. Rouse 2008. Anti-Inflammatory Effects of FTY720 Against Viral Induced
Immunopathology: Role of Drug Induced Conversion of T Cells to Become Foxp3+ Regulators.
J. Immunol. 180(11): 7636-47. Copyright © 2008 by The American Association of
Immunologists, Inc.

In this chapter ‘we’ and ‘our’ refer to co-author and me. My contributions in the paper include(1)
Selection of the topic (2) Data analysis and interpretation (3) planning experiments (4) compiling
and interpretation of literature (5) understanding how results fit into literature (6) providing
structure to the paper (7) making graphs and figures (8) writing and editing

Abstract
FTY720 has been used to control inflammatory lesions but the mechanisms by which the
drug acts in vivo are poorly understood. They may result primarily from effects on lymphocyte
and dendritic cell homing to lymphoid and inflammatory sites. We demonstrate that FTY720
may also act by causing the conversion of antigen stimulated non-regulatory CD4+ T cells to
Foxp3+CD4+ regulatory T cells and enhances their suppressive activity. In a model in which
mice were ocularly infected with HSV, daily treatment with FTY720 resulted in significantly
diminished ocular lesions. The treated animals showed increased frequencies of Foxp3+ T cells
in lymphoid organs and at two inflammatory sites viz. cornea and trigeminal ganglia. In a second
series of experiments, immunized DO11.10RAG2-/- animals, normally lacking endogenous
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Foxp3+ T cells, given FTY720 treatment developed high frequencies of Foxp3+ regulatory T
cells in lymph nodes. Some converted cells persisted in treated animals for several weeks after
drug administration was discontinued. Finally, FTY720 could effectively induce Foxp3
expressing cells from Foxp3- cells in vitro, an effect inhibited by anti-TGF-β or

the

proinflammatory cytokine IL-6. Accordingly, the anti-inflammatory effects of FTY720 could be
mediated at least in part by its ability to cause the conversion of antigen stimulated conventional
T cells to become Foxp3+ regulators. The use of FTY720 along with antigen administration
could represent a useful therapeutic means to selectively expand antigen-specific regulators
which could be valuable in many clinical situations such as allotransplants, some autoimmunties
as well as with some chronic infections.

Introduction
The fungal metabolite drug FTY720, 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3diol, has been shown to control some autoimmunities and allergic diseases as well as to suppress
transplant rejection and graft-vs-host disease (1). The drug is currently in phase III clinical for the
treatment of multiple sclerosis (2). FTY720, upon phosphorylation, is known to mimic the action
of sphingosine-1-phosphate (S1P) and acts as an agonist for four of the five S1P receptors (3).
One outcome of such binding to lymphocytes is a change in their trafficking patterns, with cells
migrating more into lymph nodes (LN) and their egress being impeded (4, 5). This may result in
lymphopenia and limited access of lesion-orchestrating lymphocytes to inflammatory sites (6).
Additionally, FTY720 may hamper dendritic cell migration into LNs as well as cytokine
production, effects that could result in immunosuppression (7). There is also evidence that
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FTY720 treatment may serve to increase the function of regulatory T cells (Tregs) (8, 9).
Accordingly, it was shown that the exposure of CD4+CD25+ T cells from mice to the
phosphorylated form of FTY720 resulted in their enhanced suppressive activity in an Ag-specific
manner. Additionally, in a model of Th1-induced autoimmunity, animals treated with FTY720
showed control over the onset and development of colitis. In the same study, an increase in the
Foxp3 mRNA at the site of inflammation was also noted, but preferential migration of Foxp3+ T
cells from elsewhere could not be excluded (9).
In the present report, we have sought to determine whether FTY720 could cause the
conversion of conventional Foxp3– T cells to Foxp3+ Tregs. In a model of virus-induced
inflammatory disease caused by HSV infection of the mouse cornea, treatment with FTY720
resulted in significantly diminished lesions. Furthermore, treated animals developed an expanded
population of Foxp3+CD4+ T cells, although in this model it was not possible to define whether
these cells were derived from preexisting Foxp3+ T cells or were converts from the Foxp3–
nonregulatory CD4+ T cells. More direct evidence that FTY720 could function to cause the
conversion of TCR-stimulated cells to Foxp3+ regulators was obtained in a TCR transgenic x
RAG2–/– model, which lacked Foxp3+ T cells (10). Treatment of such animals after immunization
with cognate Ag recognized by the TCR resulted in the induction of substantial numbers of
Foxp3+ cells that were shown to express regulatory activity in vitro. Experiments in vitro with
conventional T cells also showed that TCR activation in the presence of FTY720 and IL-2
resulted in the conversion of most surviving cells into Foxp3+ T cells. This conversion did not
require the addition of TGF-β in the cultures, although the mechanism by which FTY720
induced the conversion appeared to depend on TGF-β because the process was inhibited when
anti-TGF-β Ab was added to cultures.
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Our results show that an additional means by which FTY720 succeeds in controlling
inflammatory reactions is to cause the conversion of conventional T cells to become Foxp3+
regulators. The use of the drug along with Ag stimulation would represent a valuable means to
achieve the selective expansion of a population of regulatory cells, which would be useful in
clinical situations such as some autoimmunities, allotransplantation, and allergic diseases, as well
as in some chronic infections.

Materials and Methods
Mice, virus, biological and pharmacological reagents
Female 6- to 8-wk-old BALB/c DO11.10RAG2–/– mice were purchased from Taconic
Farms, and Thy1.2+ BALB/c and CB.17 SCID mice were purchased from Charles River
Laboratories. Foxp3-GFP knock-in animals were kindly provided by Dr. M. Oukka of Harvard
Medical School. All animals were housed in Association for Assessment and Accreditation of
Laboratory Animal Care-approved animal facilities. BALB/c DO11.10RAG2–/– and CB.17 SCID
mice were kept in our specific-pathogen free facility. HSV-1 RE was provided by Dr. Robert
Hendricks (University of Pittsburgh). It was propagated and titrated on Vero cells (ATCC
CCL81) using standard protocols. The virus was stored in aliquots at –80°C until use. All Abs
were purchased from BD Pharmingen unless otherwise stated. The Abs used for flow cytometery
were DO11.10-PE (KJ1–26), CD4-APC (RM4–5), CD25-FITC (7D4), Foxp3-PE (FJK-16s),
CD62L-FITC (MEL-14), CD103-FITC (M290), glucocorticoid-induced TNF receptor (GITR)FITC (DTA-1), CD45-APC (30-F11), and annexin V-APC. CD4-FITC (H129.9) was used for
confocal microscopy. rhTGF-β1, rIL-6, anti-TGF-β1, 2, 3 Ab (1D11), and anti-CTLA-4 Ab
(clone 6382) were obtained from R&D Systems. Anti-CD3 (145.2C11) and anti-CD28 (37.51)
94

were from BD Biosciences. rhIL-2 was obtained from Hemagen Diagnostics and FTY720 from
Calbiochem. FTY720 was dissolved in ethanol at a concentration of 10 mg/ml, and before
injecting into mice, a fresh solution was made in distilled water. For in vitro assays, FTY720 was
dissolved in ethanol at 10 mg/ml concentration, and further dilution was made in RPMI 1640
medium without additives at the time of use. SEW2871 and S1P were obtained from Cayman
Chemical and were dissolved in DMSO and 0.3 N NaOH, respectively. OVA323–339 peptide was
obtained from GenScript. CFSE was obtained from Molecular Probes and used at a final
concentration of 0.5 µM for 15 min at 37°C in PBS.
Corneal HSV-1 infections, clinical observations and treatment of mice with FTY720
Six- to 8-wk-old BALB/c mice were ocularly infected under deep anesthesia with 5 x 105
PFU HSV RE and divided randomly into four groups. Aminals in each group were treated with
three doses (0.3, 1.0, and 3.0 mg/kg body weight (BW)) of FTY720 i.p. daily starting from 24 h
postinfection (PI) until day 15 PI, respectively. In some experiments, FTY720 treatment of
infected animals was done until day 5 or day 9. Mice were observed for the development and
progression of herpetic stromal keratitis (SK) lesions and angiogenesis from day 5 until day 15,
as described elsewhere (11). The eyes were examined on different days PI and the clinical
severity of keratitis and angiogenesis of individually scored mice was recorded. The scoring
system was as follows: 0, normal eye; 1, mild corneal haze; 2, moderate corneal opacity, iris
visible; 3, severe corneal opacity, iris invisible; 4, opaque cornea, ulcer formation; and 5,
necrotizing SK. All experiments were repeated at least three times. All experimental procedures
were in complete agreement with the Association for Research in Vision and Ophthalmology
resolution on the use of animals in research.
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Induction of Foxp3 in Foxp3-CD4+ T cells by FTY720 in-vivo in immunized DO11.10
RAG2-/- mice
Six- to 8-wk-old DO11.10RAG2–/– mice were immunized i.p. with 50–100 µg of
OVA323–339 in CFA and divided into four groups. Animals in three groups were given 0.3, 1, and
3 mg/kg BW of FTY720 i.p., respectively, every alternate day for 15 days while the fourth group
was given same volume of diluent. Another group of mice was injected with PBS with CFA and
was given the above-mentioned doses of FTY720. Additionally, some immunized and FTY720(0.3 mg/kg BW) treated animals (n = 3) were given 250 µg of anti-TGF-β (1D11) Ab i.p. at days
3, 6, and 10. For some experiments, immunized animals were also treated with SEW2871 (0.3, 1,
and 5 mg/kg BW) following the same protocols as those with FTY720. For some of the
experiments, DO11.10RAG2–/– mice were immunized in the foot pad with 5 µg of OVA
emulsified with CFA in 30 µl volume. Lymphoid tissue samples were collected at different
intervals and analyzed for the expression of Foxp3, CD25, and CD4+ T cells.
In-vitro suppression assay
DO11.10RAG2–/– mice were immunized with an emulsion of OVA323–339 and CFA and
treated with FTY720 as described in the previous section. In vitro suppression assays were done
with CD4+CD25+ T cells isolated from the proximal (iliac and mesenteric) and distal (cervical,
axillary, and superficial inguinal) LNs of immunized and FTY720-treated DO11.10RAG2–/– mice
using homologous CD4+CD25– T cells and T-depleted splenocytes. Additionally, to examine the
enhancement of suppressive activity of Tregs by FTY720, DO11.10 animals were immunized
and some were treated with FTY720 for 15 days. CD4+CD25+ T cells were isolated from pooled
LNs (cervical, axillary, superficial inguinal, mesenteric, and iliac) of all of these animal groups
using a regulatory T cell isolation kit (Miltenyi Biotec) as per the manufacturer’s instructions.
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CD4+CD25– T cells were isolated either from pooled LNs (cervical, axillary, superficial inguinal,
mesenteric, and iliac) and spleens of naive DO11.10RAG2–/– mice or from those of DO11.10
animals and labeled with CFSE (0.5 µM). CD4+CD25– T cells (1 x 105) from either
DO11.10RAG2–/– or DO11.10 mice were cultured with a 2-fold serial dilution of CD4+CD25+ T
cells and 2 x 105 irradiated Thy1.2-depleted splenocytes isolated from either DO11.10RAG2–/– or
DO11.10 mice, respectively, in the presence of 1 µg/ml soluble anti-CD3. Dilution of CFSE in
stained CD4+ T cells was analyzed by flow cytometry after 72 h of incubation. For analysis of
CFSE dilution, the first gate was applied on CD4+ T cells. Of these cells, CFSE+CD4+ T cells
were then gated and the dilution of the intensity of CFSE was analyzed. In some of the
experiments, 1 µCi of tritiated thymidine was added after 48 h of incubation, and levels of
incorporation were measured 16 h later in a PerkinElmer Top Counter.
In vitro generation of Foxp3+ T cells
A modification of Chen et al.’s in vitro culture system (12) was developed for the
induction of Foxp3 in naive precursor CD4+CD25– T cells isolated from DO11.10RAG2–/– mice,
which lack their own Foxp3+ T cells (10). Total splenocytes (2 x 106) after RBC lysis and several
washings were cultured in 1 ml volume with previously optimized doses of plate-bound anti-CD3
Ab (0.125 µg/ml in 200 µl volume), rIL-2 (25 U/ml), and TGF-β (10 ng/ml) for 5 days at 37°C in
a 5% CO2 incubator in 48-well plates. In other cultures, in place of TGF-β, various
concentrations of FTY720 added daily along with IL-2 (25 U/ml) were used. In some of the
experiments, CD4+CD25– T cells purified from DO11.10RAG2–/– animals and T-depleted
irradiated splenocytes were cultured with plate-bound anti-CD3, 1 µg/ml soluble anti-CD28 Ab,
rIL-2, and FTY720 (10 ng/ml added daily). After 5 days, cells were characterized phenotypically
by flow cytometry. In some experiments, the induction of Foxp3 in Foxp3–CD4+ T cells was
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analyzed at different time points after the initiation of culture. Some of the cultures began with
CFSE-labeled splenocytes. In such cultures, dilution of CFSE was analyzed after 5 days of
incubation. In some experiments involving Foxp3 induction, anti-TGF-β1, 2, 3 Ab at a
concentration of 15 µg/ml was used to effectively neutralize TGF-β production (13). In other
experiments, rIL-6 (35 ng/ml) was used in an attempt to abrogate Foxp3 induction (14). For some
experiments, various doses of SEW2871 (1, 10, and 100 ng/ml) and S1P (10–6, 10–7, 10–8 M)
were added every 24 h instead of FTY720 into the cultures of splenocytes.
Cell sorting and transfer
CD4+ T cells were first purified from Foxp3-GFP knock-in animals using a CD4+ T cell
isolation kit, and 2 x 106 cells were transferred into nine CB.17 SCID animals. One group of
three animals was then treated with 0.3 mg/kg BW of FTY720 and another group with 3 mg/kg
BW for 15 days daily. All animals were subsequently analyzed for the proportion of GFP+CD4+
and GFP–CD4+ T cells in various lymphoid tissues. In some experiments, purified CD4+ T cells
were sorted into Foxp3-GFP+ and GFP–CD4+ T cells by a FACSVantage cell sorter (BD
Biosciences) and were then activated in vitro for 2 days using anti-CD3 and anti-CD28 mAbs in
the presence of IL-2. These cells were then mixed in 1:10 ratio (GFP+ and GFP–) and 2 x 106
cells transferred into CB.17 SCID animals, which were then treated with FTY720 and analyzed
as described above.
Flow cytometry
In vitro cultured cells, LN cells, splenocytes, peripheral blood cells, and peritoneal
exudate cells were first blocked with anti-CD32/16 mAb for 30 min and then were reacted with
fluorochrome-labeled Abs as per the manufacturer’s instructions. For Foxp3 staining, a kit from
eBioscience was used. Annexin V staining was done using a kit from BD Biosciences. For some
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of the experiments, corneas and trigeminal ganglias (TGs) were excised, pooled groupwise, and
digested with 60 U/ml Liberase (Roche Diagnostics) for 60 min at 37°C in a humidified
atmosphere of 5% CO2 as described earlier (15). After incubation, the corneas and TGs were
disrupted by grinding with a syringe plunger on a cell strainer, and a single-cell suspension was
made in complete RPMI 1640 medium. Cells were then stained as described above and were
acquired and analyzed by flow cytometery on a BD FACSCalibur using CellQuest Pro or FlowJo
softwares.
Immunflorescence and ELISA
Eyes were removed and frozen in OCT compound at 15 days p.i. Six-micrometer-thick
sections were cut, air dried, and fixed in cold acetone for 5 min. The sections were then blocked
with 3% BSA and analyzed by confocal microscopy for the presence of CD4+ T cells.
The concentrations of TGF-β and IL-17 produced in in vitro cultures were quantified by
sandwich ELISA using kits from R&D Systems. Culture supernatants were acidified before use
in the TGF-β ELISA.
Statistical analysis
Statistical significance was determined by Student’s t test. A p value of <0.05 was
regarded as a significant difference between groups *, p 0.05; **, p 0.01; ***, p 0.001.
GraphPad Prism software was used to calculate the statistical significance.

Results
FTY720 administration diminishes the severity of herpes virus induced ocular lesions
We evaluated the disease-modulating activity of FTY720 against SK induced by ocular
infection by HSV. As is evident in Fig. 3.1, A and B, infected animals treated daily with various
99

doses (0.3, 1, and 3 mg/kg BW) of FTY720 (starting 24 h PI and continued until the experiments
were terminated on day 15) developed significantly fewer stromal lesions and angiogenesis than
did untreated infected controls in a dose-dependent manner, with maximum suppression being
evident at 3 mg/kg BW dose of FTY720. For most of the subsequent experiments, a dose of 3
mg/kg BW was used. The kinetics of lesions and angiogenesis expression at a dose of 3 mg/kg
BW are shown in Fig. 3.1, C and D. The incidence of infected eyes with a lesion severity score of
3.0 was significantly higher in controls as compared with FTY720-treated animals (Fig. 3.1E).
An analysis of serial corneal sections by confocal microscopy revealed diminished CD4+ T cell
infiltration in FTY720-treated animals compared with untreated controls (Fig. 3.1F). Four
corneas from eyes with scores representing the group average were pooled from both treated and
control animals at day 10 and day 16 PI. These were analyzed by flow cytometry (after
collagenase digestion) for the presence of CD4+ T cells. Such experiments were done separately
at least three times and the data are shown in Fig. 3.1, G and H, at 16 days PI (DPI). Reduced
total numbers of CD4+ T cells were present in FTY720-treated animals, but the proportion of the
CD4+ T cells that were Foxp3+ was increased (Fig. 3.1, G and H). In the same experiment,
infiltration of CD4+ T cells was found to be reduced in the trigeminal ganglion while the
proportion of Foxp3+ T cells increased, showing that FTY720 treatment decreases the infiltration
of CD4+Foxp3– T cells but increases that of CD4+Foxp3+ at both sites of inflammation caused by
HSV-1.
FTY720 treatment after infection results in increased frequencies of CD4+CD25+Foxp3+ T
cells
That CD4+ T cell infiltrates were diminished and lesions suppressed in treated animals
could well be the consequence of the known ability of FTY720 to limit access of inflammatory T
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cells to lesion sites (6). However, as mentioned above, in ocular tissues there was an increased
frequency of Foxp3+ T cells in treated animals. Accordingly, the anti-inflammatory effect of
FTY720 might be mediated, at least in part, by a differential effect on Foxp3+ T cells. To assess
this possibility, spleens and LNs were collected at different time points PI from treated and
control animals to quantify and measure the phenotypes of CD4+ T cells. The results of a typical
experiment when the animals were treated with 0.3 (Fig. 3.2B) and 3.0 mg/kg BW (Fig. 3.2, A
and B) are depicted. As is apparent at both days 9 and 16 PI, Foxp3+CD4+CD25+ T cells were
increased in frequency in both the draining cervical LN as well as distal LNs, but not in the
spleen, especially at the early time point (Fig. 3.2, A and B). These frequency differences were
more apparent at earlier time points and were in fact already evident by 5 days PI (see Fig. 3.3).
Other experiments also measured and compared the expression of additional phenotypic markers
involved in lymphocyte homing on both Foxp3+ and Foxp3–CD4+ T cells of treated and control
LN cells. Of the markers measured (CD62L, CD103, and CD49d), the most dramatic differences
were observed with CD103 expression on Foxp3+ (but not Foxp3–) cells. Expression was
increased 6- to 7-fold in both draining LN and spleen on Foxp3+ cells from treated animals (Fig.
3.2C). This observation could explain why Foxp3+ cells were enriched in the ocular and TG
inflammatory tissues of treated animals, because CD103 is known to be a tissue-homing
molecule (16). Another homing molecule, CD49d, shown previously to be expressed on most
inflammatory cells that infiltrate the eye (15), showed no significant changes in expression levels
as a consequence of FTY720 treatment (Fig. 3.2C).
Additional experiments measured the numbers of Foxp3+ and Foxp3–CD4+ T cells
recoverable from the spleen and LNs at various times after infection of control and FTY720treated animals. In such experiments, FTY720 treatment resulted in decreased numbers of CD4+
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T cells, especially in the draining LNs and spleen, but the ratio of Foxp3+:Foxp3– cells increased
(Fig. 3.3A). These results could mean either that FTY720 caused greater retention of Foxp3+ cells
than conventional T cells in LNs (an unexpected outcome because Foxp3+ cells were reported by
others to express low levels of the S1P receptors involved in LN retention (5)) or that events such
as differential apoptosis or the conversion of some TCR stimulated Foxp3– into Foxp3+ cells. To
look for the preferential retention of Foxp3+ cells over Foxp3– cells in lymphoid organs under the
influence of FTY720 treatment, CD4+ T cells (having both fractions of CD4+Foxp3+ and
CD4+Foxp3–) purified from Foxp3-GFP knock-in animals were transferred into SCID animals,
which were then treated with two different doses (0.3 and 3 mg/kg BW) of FTY720 daily for 15
days. The lymphoid organs were analyzed after 15 days for the proportion of GFP+ and GFP–
CD4 T cells. Such experiments showed a trend for the preferential retention of Foxp3+ cells over
Foxp3–CD4 T cells, but the differences were not significant (Fig. 3.3B). This result could be
because Foxp3+ T cells could undergo more homeostatic proliferation than Foxp3–CD4+T cells
under the influence of FTY720. In some of the experiments, sorted Foxp3+ and Foxp3– CD4+ T
cells were separately activated in vitro for 2 days in the presence of anti-CD3, anti-CD28 mAbs,
and IL-2 and were then transferred in a 1:10 ratio (Foxp3+-Foxp3–) into SCID recipients.
Subsequently, the proportions of Foxp3– and Foxp3+ cells were analyzed in lymphoid tissues
after 15 days of FTY720 treatment. Such experiments revealed no significant differences in the
proportions of Foxp3– and Foxp3+ T CD4+ T cells in the FTY720-treated and control animals,
indicating that differential retention of either cell types in the lymphoid organs did not occur
(data not shown).
Looking at the differential apoptosis of Foxp3– cells over Foxp3+ cells, we used Foxp3GFP knock-in mice that were infected with HSV-1, with some being treated with FTY720 (either
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0.3 or 3.0 mg/kg BW). After 15 days, draining and distal (superficial inguinal) LNs were
analyzed for evidence of apoptosis in Foxp3+ and Foxp3–CD4+ T cells. We could find no
evidence for differential apoptosis of either Foxp3– or Foxp3+ cells in treated vs control animals
(Fig. 3.3C). However, a trend in increased apoptosis of Foxp3–CD4+ T cells was observed in the
nondraining LNs, which could result from the suppressive effects of Tregs on effector T cells, as
the former are present more abundantly in the nondraining LNs than in draining cervical LNs. In
a separate experiment, when HSV-1-infected animals were treated with FTY720 after day 8 PI, a
time when viral Ags were no longer present, we did not find increased frequencies of
Foxp3+CD4+ T cells. This finding could support the idea that FTY720 causes the conversion of
TCR-stimulated conventional T cells to become Foxp3+ regulators
Animals without Foxp3+ T cells exposed to antigen in the presence of FTY720 develop
Foxp3+ T cells
Evidence that TCR-stimulated Foxp3–CD4+ T cells may convert to Foxp3+ regulatory
cells was obtained in TCR transgenic x RAG2

–/–

mice, which are well known to lack Foxp3+ T

cells (10). This observation was also confirmed in our studies (Fig. 3.4A). In these experiments,
DO11.10RAG2–/– mice were immunized i.p. with OVA323–339 peptide in CFA, and some animals
were additionally treated on alternate days with various doses (0.3, 1.0, or 3.0 mg/kg BW) of
FTY720 starting 24 h after immunization. Experiments were usually terminated on day 15 to
assess the presence of Foxp3+CD4+ T cells in various lymphoid tissues. Whereas a few Foxp3+ T
cells were induced in immunized but untreated animals, Foxp3+ cells accounted for a major
percentage of CD4+ T cells in those animals given FTY720 (Fig. 3.4A). In fact, such cells were
present in surprisingly high frequencies (Fig. 3.4B) both in LNs proximal to the site of
immunization (iliac and mesenteric) as well as in distal (cervical, axillary, and superficial
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inguinal) LNs. The increase in Foxp3+ T cell percentages followed a dose dependency of
FTY720 treatment, with the highest frequencies being observed at 3 mg/kg BW. Among CD4+ T
cells, the average frequencies of Foxp3+CD4+ T cells were 63% in cervical (range 55–75%), 60%
in axillary (range 52–65%), 48% in superficial inguinal (range 36–52%), 15% in iliac (range 12–
25%), and 10% in mesenteric (range 6.8–15%) LNs (Fig. 3.4B). Lesser frequencies of
CD4+Foxp3+ T cells were evident in the spleen (range 2–6%) (Fig. 3.4, A and B). The absolute
numbers of Foxp3+ T cells in various organs vary, but they were significantly higher in cervical,
axillary, and superficial inguinal LNs of FTY720-treated animals as compared with controls (Fig.
3.4C). Some experiments were terminated at day 5 after FTY720 treatment. Some converted
cells were already present at this time (up to 20% of CD4+ T cells were Foxp3+). In other
experiments, lymphoid tissues were examined at 40 DPI (FTY720 treatment ended at day 30)
and at day 75 PI (FTY720 treatment ended at day 15). In such animals up to 20–30% and 5–10%,
respectively, of CD4+ T cells were Foxp3+ in all lymphoid organs including the spleen, indicating
that the converted cells may redistribute among all LNs and spleen in the absence of FTY720
treatment and persist for a prolonged period.
Some experiments were performed with DO11.10RAG2–/– mice to investigate the
mechanisms involved in the induction of Tregs with FTY720. Thus, DO11.10RAG2–/– mice
immunized with OVA peptide were treated every alternate day with SEW2871 (0.3, 1 and 5
mg/kg BW), a specific agonist of the S1P1 receptor. After 15 days, animals were sacrificed and
lymphoid tissues were analyzed for CD4, CD25, and Foxp3. As shown in Fig. 4.4D, animals
develop increased frequencies of Foxp3+ T cells as compared with untreated animals, but these
frequencies were far less than those found in FTY720-treated animals. This may be because
FTY720 engages more than just the S1P1 receptor. Additional experiments were done to see
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whether TGF-β blocking in vivo could have some effects on the accumulation of Tregs. AntiTGF-β1, 2, 3 mAb (250 µg/ml) was injected i.p. at days 3, 6, and 10 in immunized and FTY720treated animals. Lymphoid tissues were collected after 15 days and analyzed for
CD4+CD25+Foxp3+ T cells. TGF-β-neutralized animals developed significantly fewer Tregs as
compared with control animals (Fig. 3.4B).
Curiously, the highest frequencies of Foxp3+CD4+ T cells induced in immunized
FTY720-treated animals were usually in LNs that were not considered as draining LNs to the
immunization site. This pattern of events was also evident as early as 5–7 days after
immunization and was also seen when the site of immunization was in the neck region (data not
shown). At present, we have no explanation for these observations, but they may reflect Ag
dissemination to distal sites, especially following i.p. immunization along with inhibition of
Tregs by inflammatory cytokines that are likely to be more abundant in the local LNs. In
additional experiments, Ag was given in the foot pad, which we surmised might limit the spread
of Ag to distal LNs. However, even with these experiments, increased frequencies of Foxp3+ T
cells were found in non-draining LNs (36 ± 8% in CLN, 28 ± 4% in sup Ig LN) as compared
with draining popliteal LNs (10 ± 4.3%). Understanding why distal tissues develop more Foxp3+
cells requires further investigation.
In vivo converted Foxp3+CD25+CD4+ T cells express regulatory activity
To demonstrate that FTY720-converted Foxp3+ cells in DO11.10RAG2–/– mice expressed
regulatory activity in vitro, CD4+CD25+ T cells were isolated from both the proximal and distal
LNs 15 days after immunization of FTY720-treated animals. Of these CD25+ cells, >90% were
additionally Foxp3+ (Fig. 3.5A). As is evident from Fig.3.5B, the CD4+CD25+ T cells isolated
from both proximal and distal LNs suppressed in a dose-dependent manner the proliferation of
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anti-CD3-stimulated, CFSE-labeled CD4+CD25– T cells isolated from pooled spleens and LNs of
DO11.10RAG2–/– naive animals. It was interesting to observe differences in the levels of CD25
on Foxp3+ T cells among proximal and distal LNs, with cells isolated from distal LNs showing
lower levels of CD25 expression. This observation might be explained by the differential
availability of cytokines in the draining vs non-draining LNs that drive CD25 expression, but
these issues require further investigation. Despite differences in CD25 levels, the in vitro
suppressive activity of Tregs isolated from these sites was not significantly different.
Experiments were also done to compare the in vitro regulatory activity of CD4+CD25+ T cells
isolated from immunized and immunized plus FTY720-treated immunocompetant animals, which
do have naturally occurring Tregs. For this purpose, DO11.10 animals were used. CD4+CD25+ T
cells were isolated and pooled from cervical, axillary, superficial inguinal, mesenteric, and iliac
LNs of both groups. Approximately 80% of these cells also expressed Foxp3 (Fig. 3.5C). The
responder cells (CD4+CD25–) were isolated from pooled spleens and LNs of DO11.10 naive
animals. As shown Fig. 3.5D, the CD4+CD25+ T cell population from FTY720-treated animals
showed higher in vitro activity than did those from untreated animals in a dose-dependent
manner. Thus, in addition to expanding the population of Tregs, the cells also appear to show
enhanced regulatory activity when measured in vitro. In a previous report, FTY720 treatment of
CD4+CD25+ Tregs in vitro was shown to enhance their regulatory activity (8).
FTY720 can induce Foxp3 expression in antigen stimulated CD4+ T cells in vitro
Our above in vivo experiments indicate that CD4+ T cells may be converted to express
Foxp3 and become regulatory when Ag stimulated in the presence of FTY720. To establish more
directly whether FTY720 can cause Foxp3– cells to convert to Foxp3+, in vitro experiments were
performed. In such experiments, whole splenocytes from naive DO11.10RAG2–/– animals were
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stimulated with plate-bound anti-CD3 either in the presence of optimal amounts of TGF-β (our
unpublished data) or with varying concentrations of FTY720, both along with human rIL-2.
FTY720, which is less stable in aqueous solution, was added to the cultures every 24 h. As
shown in Fig. 3.6A, 77% (range for >10 experiments of 75–94%) of viable CD4+ T cells became
Foxp3+ after 5 days of culture in the presence of TGF-β. In cultures containing FTY720, 54%
(range for five experiments of 30–55%) of CD4+ T cells became Foxp3+. The optimal FTY720
concentration was found to be 10 ng/ml when added daily (Fig. 3.6B). The in vitro-generated
Foxp3+ T cells were also analyzed for other phenotypic markers. Most cells were additionally
CD25+, CD62Lhigh, and GITR+, showing essentially the same phenotype as TGF-β-converted
cells (Fig. 3.6E). However, the expression of CD103 was delayed, and maximal numbers of
Foxp3+ cells become CD103+ after 6 days of incubation. In some experiments, cells were tested
for Foxp3 conversion at different times after culture initiation. As shown in Fig. 3.6C, some
conversion could be detected at day 2, but numbers increased over the culture period, reflecting
perhaps the conversion of a new subpopulation each time the FTY720 was added. However, the
observation could also reflect the proliferation of already converted cells. That proliferation of
Foxp3+ cells was occurring was shown when CFSE-labeled splenocytes were stimulated with
anti-CD3 and IL-2 in the presence of FTY720. The newly differentiated Foxp3+ T cells
underwent multiple rounds of divisions (Fig. 3.6D). Therefore, FTY720 in the presence of IL-2
causes differentiation as well as proliferation of Tregs in vitro.
FTY720 mediated Foxp3 induction is TGF-β dependent
At present, we have no understanding as to the mechanism by which FTY720 induces
TCR-stimulated T cells to express Foxp3. It is known, however, that FTY720 binding to the S1P1
receptor may trigger some downstream events that are in common with those induced by TGF-β
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(17, 18). The results expressed in Fig. 7A indicate that the mechanism by which FTY720 acts
may in fact involve TGF-β. Thus, the addition of neutralizing anti-TGF-β1, 2, 3 Abs to culture
stimulated with FTY720 markedly inhibited the percentage of CD4+ T cells that became Foxp3+
(Fig. 3.7, A and B). Additionally, supernatants of FTY720-stimulated cultures were shown to
contain higher concentrations of TGF-β than the control supernatants, an effect that was
dependent on the dose of FTY720 used (Fig. 3.7C). Accordingly, the mechanism by which
FTY720 induces Foxp3 expression in CD4+ T cells may proceed via the induction of TGF-β. The
source of TGF-β in the splenocyte culture seems to be accessory cells, as no conversion was
observed when purified populations of CD4+ T cells were stimulated with anti-CD3 and antiCD28 Abs in the presence of FTY720 and IL-2 (data not shown). This notion was further
supported by experiments wherein neutralization of CTLA-4 was achieved using anti-CTLA-4
Ab in the FTY720 induction cultures. With CTLA-4 neutralization, the frequencies of cells
expressing Foxp3 were reduced significantly (Fig. 3.7B). However, the cell type involved in
secreting TGF-β remains to be identified.
It has been suggested that proinflammatory cytokines such as IL-6 could neutralize the
effect of Foxp3 induction and, along with TGF-β, induce the IL-17-producing cells (14).
Therefore, we examined the effect of IL-6 addition in the FTY720 Foxp3-converted cultures. In
such experiments, the addition of IL-6 to such FTY720-induced cultures markedly reduced the
formation of Foxp3+ T cells, while at the same time such addition led to the induction of some
cells in the cultures that produced IL-17 (Fig. 3.7, B and D). The observation that IL-6, and
perhaps other inflammatory cytokines, may inhibit the induction of Foxp3+ T cells may explain
in part why the frequency of Foxp3+ cells in the draining LNs, where cytokines are more likely to
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be present especially early after infection or immunization, was less than in some distal LNs.
These issues are under further investigation.
Some experiments were done to investigate the role of other S1P receptor agonists such
as SEW2871 and S1P in the Foxp3 induction process. These compounds were added daily to the
in vitro cultures of anti-CD3- and IL-2-stimulated splenocytes, which were then analyzed after 5
days for the expression of Foxp3+ in CD4+ T cells. Such experiments showed a small but
significant increase in the Foxp3+ T cells with SEW2871 treatment, but these numbers were not
significant with S1P (Fig. 3.7E).

Discussion
The present report documents the efficacy of FTY720 in inhibiting the severity of
immunoinflammatory lesions caused by ocular infection with HSV. Our results showed that the
use of the drug after infection significantly reduced disease, an effect that could be the
consequence of the well-documented ability of FTY720 to retain T cells and some other cell
types in LNs, thereby diminishing their access to tissue sites of inflammation (6). However, we
also noted an expansion of Foxp3+ Tregs in the FTY720-treated animals, which could also
explain, at least in part, the reduced lesions in the FTY720-treated animals because SK lesion
severity is known to be influenced by naturally occurring Tregs (15). We interpreted our
observations to mean that the source of the expanded Foxp3+ population could represent
conversion of Ag-stimulated conventional CD4+ T cells to become Foxp3+ and regulatory in
function.
More direct evidence that FTY720 could cause the conversion of Foxp3– to Foxp3+ T
cells was obtained by additional in vivo and in vitro studies. The in vivo evidence came from the
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use of TCR transgenic x RAG2–/– mice, which are known to possess few if any Foxp3+ Tregs
(10). Exposure of such animals to Ag along with FTY720 treatment resulted in the development
of high frequencies of Foxp3+CD4+ T cells in many LNs. Finally, the most convincing evidence
that exposure of Ag-stimulated Foxp3–CD4+ T cells could be converted by exposure to FTY720
to become Foxp3+ Treg came from in vitro studies. Accordingly, the addition of FTY720 daily to
TCR-stimulated Foxp3– T cells in the presence of IL-2 resulted in the conversion of substantial
numbers of cells to Foxp3+ over a 5-day culture period. This conversion did not require the
addition of extraneous TGF-β, although the conversion process could involve the induction of
TGF-β because the addition of anti-TGF-β Ab to cultures markedly diminished the production of
Foxp3+ T cells. The effect of TGF-β neutralization on accumulation of Foxp3+ T cells was also
evident in in vivo experiments. The use of FTY720 given along with Ag could represent a useful
way to achieve the selective expansion of Ag-specific regulators, which could be valuable in
many clinical situations such as allotransplants, some autoimmunities, as well as with some
chronic infections.
One curious observation we made in both FTY720-treated HSV infected and immunized
DO11.10RAG2–/– animals was that the frequency of Foxp3+ T cells was usually higher in LNs
distal to the site of infection or immunization than was evident in the proximal LNs, which likely
took up most of the Ag. At present, we have no explanation for this observation, but it could
reflect differential redistribution of Foxp3+ and CD4+ effectors from the proximal LN site of
induction. This might occur, as others have reported that naturally occurring Tregs express lower
levels of the S1P receptors involved in LN retention than other T cell subsets (8). This could
mean that Tregs are less likely than activated effectors to be retained in the proximal LNs,
especially during FTY720 treatment, and hence are more able to disseminate to other sites. An
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alternative idea is that Tregs at proximal sites may be partially blunted by proinflammatory
cytokines that could be present at higher concentrations in proximal LNs, especially early after
infection and immunization. A third explanation may relate to the levels of Ag available to
induce Foxp3+ Tregs at proximal and distal sites. In this context, others have shown that very low
levels of Ag may be more effective at inducing Foxp3+ Tregs than are higher doses (19, 20).
Such low levels, possibly conveyed there by dendritic cells, are likely to be present at distal sites
compared with those in the proximal LN. Additional experiments are under way in an attempt to
explain high frequencies of Foxp3+-converted cells in distal LNs.
Although our in vitro studies demonstrate that FTY720 may induce the conversion of
TCR-stimulated conventional T cells into Foxp3+ regulators, the mechanism by which this occurs
remains to be explained. The conversion process did not require the addition of TGF-β, but the
mechanism could involve the induction of TGF-β either in the converting T cells themselves or,
as we consider more likely, in accessory cells in the cultures. Such accessory cells might also be
responsible for phosphorylation of the drug, which appears to be a necessary step for it to bind
effectively to the S1P receptors (3, 21). We are currently attempting to determine which cells
types in our culture system act as the source of the sphingosine kinases involved in the FTY720
phosphorylation or whether this activity is independent of the phosphorylation state of the drug,
as has been reported for some activities of FTY720 (22).
Our studies also indicate that one means by which the FTY720-induced Foxp3
conversion occurred could involve TGF-β induction as an intermediate step. In support of this,
fluids in FTY720-treated cultures contained higher levels of TGF-β than found in control
cultures. Moreover, the addition of neutralizing Abs to TGF-β markedly diminished the FTY720induced conversion process. It was also of interest that in cultures that contained IL-6, but no
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TGF-β, the addition of FTY720 resulted in the induction of increased amounts of IL-17
production compared with cultures lacking FTY720. This observation may also argue that
FTY720 functions by causing the production of TGF-β from some cell types, because this
cytokine, along with IL-6, is known to be a stimulus for Th-17 cell induction (14). The
observation might also mean that FTY720 will be a better inducer of Foxp3+ Tregs if used when
levels of proinflammatory cytokines are low.
Sakaguchi et al.’s seminal observations in the mid-1990s (23) reawakened interest in
Tregs and opened up the prospect of using these cells immunotherapeutically. However, in
normal individuals, most Foxp3+ Tregs are considered to be thymus-derived and are largely
reactive to a range of self Ags (24). For therapeutic purposes, it would be preferable to use Tregs
of known Ag specificity so as to increase potency and avoid potential side effects of inhibiting
desirable immune responses (25). Some have expanded specific self-reactive Tregs in vitro and
demonstrated in vivo efficacy using adoptive transfer approaches (25). Such approaches,
however, are cumbersome and extremely expensive. A better way would be to expand the Treg
population in vivo to the Ag of choice. This may be accomplished by approaches such as the one
we have described in the present report wherein Foxp3+ cells with regulatory function are
converted from conventional Ag-stimulated nonregulatory precursors. That such conversion can
be accomplished was appreciated some time ago by the Horwitz and Wahl groups who showed
that TGF-β stimulation was a key event for the conversion process (12, 26). This was supported
by elegant studies from Bettelli and colleagues, who defined in vitro conditions to generate Agspecific Foxp3+ Tregs as well as proinflammatory IL-17-producing cells (14). More recently,
several independent groups observed that retinoic acid may also be involved in the Foxp3
conversion process (13, 27, 28, 29). At least with mouse T cells, conversion by retinoic acid
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additionally requires TGF-β stimulation (13, 27, 28, 29), but this may not be the case with human
cells (30). Recently, other molecules have also been shown to facilitate the conversion of Agstimulated conventional T cells to become Foxp3+ regulators (31, 32).
We would argue that the approach we have described in this report represents a valuable
one in terms of therapy for chronic inflammatory diseases. Thus, as is well known, FTY720 has a
potent anti-inflammatory activity because of its known effect on lymphocyte sequestration (4).
However, its ability to expand and activate Foxp3+ Tregs to an Ag of choice could prove
particularly useful, because this should avoid the unwanted side effects that polyclonal Treg
populations might exert. It will be particularly important to determine how long FTY720converted cells remain in the body as functional regulators after treatment has been discontinued.
So far, we have only studied animals up to 10 wk posttreatment and found that some cells with
the converted phenotype are still present. Further long-term studies are currently under way.
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Figure 3. 1 FTY720 treatment diminishes SK lesion severity and increases the
representation of Foxp3+CD4+ T cells at inflammatory sites
BALB/c mice were infected ocularly with 5x105 HSV I (RE) and some were additionally treated
with FTY720 daily from 24 hrs until day 15 p.i. as described in Materials and Methods. Lesion
severity (A) and angiogenesis (B) were scored. The lesion severity and angiogenesis were
diminished in FTY720 treated animals. The incidence of HSK 15dpi is shown (positive if score ≥
3.0) (C). D. Representative corneal sections were stained for CD4+ T cells (see arrows) and
analyzed by confocal microscopy 15dpi. (E) Single cell suspension was made from the cornea
and trigeminal ganglias (TGs) digested with liberase and stained for Foxp3, CD4 and CD45
(leukocyte marker) 10 days post infection. Representative FACS plots from pooled corneas (left
panel) and TGs (right panel) of control and FTY720 treated animals are shown (Gated on
CD45+CD4+ cells). The proportions of Foxp3+CD4+ T cells was increased both in corneas and
TGs of FTY720 treated animals
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Figure 3. 2 FTY720 treatment early after ocular HSV infection increases the frequencies
and alters the phenotype of CD4+CD25+Foxp3+ T cells in lymphoid organs.
Lymphoid organs (spleens and LNs) from control and FTY720-treated BALB/c animals (as in
Fig. 1) were processed at day 9 and day 16 PI and analyzed by flow cytometry. A, Representative
FACS plots for the staining of CD4, CD25, and Foxp3 from spleen and draining (cervical), and
distal (superficial inguinal) LNs of control and FTY720-treated (3 mg/kg BW) animals are
shown at days 9 (left panel) and 16 PI (right panel) (gated on CD4+ T cells). B, Relative
frequencies of CD4+CD25+Foxp3+ T cells in spleen and draining (cervical) and distal (superficial
inguinal) LNs as measured by flow cytometry at 9 (left panel) and 16 DPI (right panel) are
shown. The frequencies of CD4+CD25+Foxp3+ T cells are increased in the lymphoid organs. The
statistical significance was determined by Student’s t test. C, Expression of CD62L, CD103, and
CD49d was examined at day 16 PI on Foxp3+ and Foxp3–CD4+ T cells obtained from the spleens
and draining LNs of control and FTY720-treated animals (as in Fig. 2A) by flow cytometry.
FTY720 treatment changes the expression pattern of some of the homing molecules specifically
on Foxp3+ T cells.
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Figure 3. 3 FTY720 treatment increases the representation of Foxp3+ T cells over
CD4+Foxp3– T cells in the lymphoid organs.
A, Ratios of absolute numbers of Foxp3+CD4+ T cells and Foxp3–CD4+ T cells in spleen,
cervical LNs, and superficial inguinal LNs at days 5, 10, and 16 are shown. B, CD4+ T cells (2 x
106) (containing both Foxp3+ and Foxp3–) from Foxp3-GFP knock-in animals were transferred
into SCID animals, which were then treated with FTY720 (0.3 and 3.0 mg/kg BW) daily for 15
days, and lymphoid organs were then analyzed for percentages of GFP+CD4+ and GFP–CD4+ T
cells. No significant differences were found in treated and untreated animals. C, Foxp3-GFP
knock-in animals were infected with HSV-1 (5 x 103 PFU) ocularly and treated with FTY720
(0.3 and 3.0 mg/kg BW) for 15 days. On day 16, draining cervical (upper panel) and distal
superficial inguinal (lower panel) LNs were analyzed for evidence of annexin V+GFP+ and GFP–
CD4+ T cells. Representative FACS plots from three animals studied are shown.
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Figure 3. 4 FTY720 administration along with Ag immunization induces Foxp3 expression
in CD4+ T cells in vivo.
DO11.10RAG2–/– mice were immunized i.p. with OVA in CFA and some (n = 6–7/group) were
additionally treated with FTY720 (0.3, 1.0, and 3.0 mg/kg BW) on alternate days starting from
24 h postimmunization and continued until day 15. At 16 days of treatment, spleen and proximal
(iliac and mesenteric) and distal (cervical, axillary, and superficial inguinal) LNs were isolated
and analyzed for CD4+CD25+Foxp3+ T cells by flow cytometry (gated on CD4+ T cells). A,
Representative FACS plots for percentages of CD4+CD25+Foxp3+ T cells from six to seven
different experiments are shown when animals were treated with 3.0 mg/kg BW of FTY720. B,
Bar diagram for percentages of CD4+Foxp3+ T cells from six to seven different experiments is
shown. Three animals immunized and FTY720-treated (0.3 mg/kg BW) were additionally given
250 µg of anti-TGF-β Ab at days 3, 6, and 10 and percentages of CD4+Foxp3+ T cells in
lymphoid organs analyzed at 15 day are shown. C, Absolute numbers of CD4+Foxp3+ T cells in
lymphoid tissues of immunized controls and immunized plus FTY720-treated (0.3 and 3.0 mg/kg
BW) animals are shown. D, DO11.10RAG2–/– animals were immunized and treated with
SEW2871 (0.5, 1.0, and 5.0 mg/kg BW) as described for FTY720 treatment. After 15 days,
percentages of Foxp3+CD4+ T cells in various lymphoid tissues were analyzed.
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Figure 3. 5. FTY720-induced Foxp3+CD25+CD4+ T cells are immunosuppressive.
CD4+CD25+ T cells were isolated from immunized and immunized plus FTY720-treated
DO11.10RAG2–/– and DO11.10 animals were used in suppression assays against the cultures of
CD4+CD25– T cells from naive DO11.10RAG2–/– and DO11.10 mice, respectively, stimulated
with anti-CD3 Ab as described in Materials and Methods.
In A and B, DO11.10RAG2–/– animals were used; in C and D, DO11.10 animals were used. A,
CD4+CD25+ T cells were purified from pooled proximal (iliac and mesenteric) and distal
(cervical, axillary, and superficial inguinal) LNs of FTY720-treated immunized DO11.10RAG2–
/–

animals to the extent of 90% (left panel). FACS plot for purified CD4+CD25+ cells from

proximal LNs is shown. A representative histogram of CD4+CD25+ T cells that were Foxp3+ is
shown (right panel). Ninety to 95% of CD4+CD25+ T cells were Foxp3+ from both pooled
proximal and distal LNs. Isotype control staining is shown (middle panel). B, Representative
FACS plots are shown to demonstrate the suppressive activity of CD4+CD25+ T cells from
immunized and FTY720-treated DO11.10RAG2–/– animals. CD4+CD25– T cells showing that
intensity of CFSE is decreased when these cells were cocultured with CD4+CD25+ T cells at 1:1
and 1:4 ratios (Treg-to-effector T cells) from proximal (prox) LN (upper panel) and distal (dis)
LN (middle panel). Lower panel, Overlap of FACS plot for comparison of suppressive activity of
Tregs isolated from draining LNs and peripheral LNs. C, Proportions of Foxp3+ T cells among
CD4+CD25+ T cells isolated from immunized and immunized plus FTY720-treated animals are
shown. D, Inhibition of CD4+CD25– T cell proliferation in presence of CD4+CD25+ T cells from
immunized and immunized plus FTY720-treated animals is shown (% inhibition = cpm of
CD4+CD25– T cells – cpm of CD4+CD25– T cells and CD4+CD25– coculture/cpm of
CD4+CD25– T cells x 100).
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Figure 3. 6 In vitro generation and phenotypic characterization of FTY720-induced Foxp3+
T cells.
A, Splenocytes were cultured in the presence of 25 U of rIL-2 and the indicated concentrations of
TGF-β as a positive control or FTY720. More than 99% of CD4+ T cells were KJ1–26 positive
(gated on CD4+ T cells). After 5 days of culture, cells were analyzed for the expression of CD4,
Foxp3, and CD25. B, Dose response histogram for Foxp3 induction with FTY720 from a typical
experiment is shown. A dose of 10 ng/ml FTY720 when added daily in the culture was found to
convert optimally Foxp3– cells into Foxp3+CD4+ T cells. C, Kinetic analysis of in vitro induction
of Foxp3 in CD4+CD25–Foxp3– T cells with TGF-β (10 ng/ml) and FTY720 (10 ng/ml) is
shown. Representative FACS plots of three similar experiments are shown. D, Splenocytes from
DO11.10RAG2–/– animals were CFSE labeled and cultured with plate-bound anti-CD3, IL-2, and
FTY720 or TGF-β as a positive control for 5 days. After 5 days, cells were stained with CD4 and
Foxp3. CFSE dilution and Foxp3 expression were shown in gated CD4+ T cells. FTY720induced CD4+CD25+Foxp3+ T cells proliferate extensively. E, The phenotype of in vitrogenerated Foxp3+ T cells by FTY720 and TGF-β as percentage positive for indicated surface
marker is shown.
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Figure 3. 7 TGF-β is involved in FTY720-mediated Foxp3 induction in CD4+Foxp3– cells.
A, Anti-TGF-β1, 2, 3 Abs or IL-6 was added in the splenocyte cultures in the presence of TGF-β
(upper panel) and FTY720 (lower panel), and surviving CD4+ T cells were analyzed for Foxp3
expression (CD4 gate). B, Percentages of Foxp3+ cells of CD4+ T cells are shown in splenocyte
cultures added with anti-TGF-β (20 µg/ml), IL-6 (35 ng/ml), and anti-CTLA-4 Ab (20 µg/ml). C,
Dose response bar diagram of TGF-β concentration in culture supernatants of splenocytes added
with different doses of FTY720 is shown. D, IL-17 concentrations from culture supernatants of
splenocytes in the presence of IL-2 only and IL-2 with TGF-β or TGF-β + IL-6 or FTY720 or
FTY720 + IL-6 as measured by sandwich ELISA are shown. E, Bar diagram showing the
percentages of Foxp3+ cells induced with TGF-β, FTY720, SEW2871, and S1P is shown.
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PART IV
ROLE OF TIM-3/GALECTIN-9 INHIBITORY
INTERACTION IN VIRAL INDUCED
IMMUNOPATHOLOGY: SHIFTING THE BALANCE
TOWARDS REGULATORS
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Research described in this chapter is from a paper submitted for publication in Journal of
Imunology by Sharvan Sehrawat, Amol Suryawanshi, Mitsuomi Hirashima and Barry T. Rouse.

Sehrawat S, Suryawanshi A, Hirashima M and Rouse BT. Role of TIM-3/galectin-9 inhibitory
interaction in viral induced immunopathology: Shifting the balance towards regulators. (Journal
of Immunology-Submitted)

In this chapter “our” and “we” refers to me and co-authors. My contribution in the paper includes
(1) Selection of the topic (2) Compiling and interpretation of the literature (3) Designing
experiments (4) understanding the literature and interpretation of the results (5) providing
comprehensible structure to the paper (6) Preparation of graphs and figures (7) Writing and
editing

Abstract
Controlling chronic immunoinflammatory diseases such as lesions in eye caused by
infection with herpes simplex virus (HSV) represents a major therapeutic challenge. Since CD4+
T cells are the primary orchestrators of lesions caused by HSV, targeting activated CD4+ T cell
subsets and increasing the representation of cells that express regulatory function would be a
logical therapeutic approach. We show in this report that this outcome can be achieved by
therapy, systemic or local, with the lectin-family member galectin-9. This molecule, which is a
natural product of many cell types, acts as a ligand to the inhibitory molecule TIM-3 that is
expressed by activated but not naïve T cells. We show that 50% or more of T cells in ocular
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lesions caused by HSV in mice express TIM-3 and that blocking signals from its natural ligand
with a monoclonal antibody results in more severe lesions. More importantly the provision of
additional galectin-9, either systemically or more effectively by local subconjuctival
administration, diminished the severity of SK lesions as well as the extent of corneal
neovascularization. Multiple mechanisms were involved in inhibitory effects. These included
apoptosis of the orchestrating effector T cells with consequent reduction of proinflammatory
cytokines, an increase in the representation of two separate subtypes of regulatory cells as well as
inhibitory effects on the production of molecules involved in neovascularization, an essential
component of SK pathogenesis. Our results indicate that galectin-9 therapy may represent a
useful approach to control HSV induced lesions, the commonest cause of infectious blindness in
the Western World.

Introduction
One of the dire consequences of herpes simplex virus (HSV) infection is blindness
resulting from infection in the eye and a subsequent chronic inflammatory reaction in the corneal
stroma. This lesion is considered to be immunopathological orchestrated by T lymphocytes that
recognize peptides derived from viral proteins or perhaps from altered self proteins of the
damaged cornea (1, 2). Currently, herpetic stromal keratitis (HSK) is mainly controlled by
combinations of drugs that include antivirals and steroids with the latter being administered for
prolonged periods of time (3). Future therapies are expected to emerge from a better
understanding of the disease pathogenesis so that critical steps can be counteracted more
precisely. Identifying such steps has come mainly from studies in animal models, especially the
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mouse, where lesions that closely resemble those in humans can routinely be induced following
primary infection with appropriate strains of virus (4). Such studies have revealed a critical role
of CD4+ T cells of the Th1 subset as mediators of lesions (5, 6). In consequence, either
preventing the access of Th1 cells to the eye or blunting their activity once at ocular sites
represents potentially a valuable form of therapy. Recent studies on some autoimmune lesions
caused by pathogenic T cells have indicated that one means of terminating the activity of such T
cells is to engage receptors expressed by activated cells that deliver an inhibitory or lethal signal
to the cell (7-11). This effect was achieved in some situations by engaging the TIM-3 (T cell
immunoglobulin and mucin-3) receptor, a member of the T cell immunoglobulin and mucin
family of proteins, with its recently identified ligand galectin-9 (8). Accordingly, the resolution
of autoimmune lesions in collagen arthritis (a CD4+ Th1 subset mediated autoimmune lesion)
occurred following treatment with galectin-9 (12). Some measure of control was also achieved
with galectin-9 treatment in other immunoinflammatory lesions such as experimental
autoimmune encephalomyelitis and graft versus host disease (8, 13, 14). To our knowledge, a
role for TIM-3 galectin-9 interaction in controlling inflammatory lesions caused by microbial
agents has yet to be explored. The present studies were designed, therefore, to evaluate if lesions
in the eye caused by HSV were subject to control by manipulating the TIM-3/galectin-9 system
on one or more cell types involved in causing HSK.
Our studies demonstrate that galectin-9 and TIM-3 interaction does influence the
expression of lesions in the eye following ocular infection with HSV. Accordingly, lesions were
significantly more severe if the signals delivered to TIM-3 were interrupted using anti-TIM-3
antibody. Moreover if galectin-9 was supplied in excess, either by systemic or local
administration,

lesion

severity,

which

included
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particularly

the

extent

of

ocular

neovascularization, was diminished. The mechanisms by which galectin-9 acted in vivo were
likely multiple. These included induction of apoptosis of pathogenic effector Th1 cells, induction
or the expansion of two types of regulatory cells as well as the diminished production of some
factors involved in corneal neovascularization. Influencing the function of the TIM-3/galectin-9
pathway holds promise as a means to control the severity of HSK lesions.

Materials and Methods
Mice, Virus, cell lines
Female 6- to 8-wk-old C57B/6 mice were purchased from Harlane Sprague-Dawley
(Indianapolis, IN). GFP-Foxp3 Knock-in mice were a kind gift from Dr. M. Oukka of Brigham
and Women Hospital, Harvard Medical School. All animals were housed in the animal facilities
at the University of Tennessee. BALB/c DO11.10 RAG2-/- mice were purchased from Taconic
Farm and kept in our specific pathogen-free facility where food, water, bedding, and instruments
were autoclaved. All manipulations were done in a laminar flow hood. All experimental
procedures were in complete agreement with the Association for Research in Vision and
Ophthalmology resolution on the use of animals in research. HSV-I RE Tumpey and HSV-I RE
Hendricks was propagated and titrated on Vero cells (ATCC CCL81) using standard protocols.
The virus was stored in aliquots at -80°C until use.
Antibodies and reagents
CD4-APC (RM4-5), DO11.10-PE (KJ1.26), CD25-FITC (7D4), CD103-FITC (M290),
CD62L-APC (MEL-14), CD44-FITC (1M7), Foxp3-PE(FJK-16s), Foxp3-FITC (FJK-16s),
CD69-FITC (H1.2F3), CD11c-PE (HL3), CD11c-APC (HL3), anti-IFN- -FITC, anti-IL-17-PE,
CD11b-PerCP ( M1/70), Gr1-PE (RB6-8C5), Gr1-FITC (RB6-8C5), F4/80-FITC (BM8), Ly6C139

FITC (AL-21 ), anti-CD3 (145.2C11), and anti-CD28 mAb (37.51) were purchased from BD
PharMingen (San Diego, CA). Anti-TIM3-APC (cat.# FAB1529A), anti-TIM-3-PE (cat.#
FAB1529P), recombinant IL-6 and recombinant human TGF-β1 were obtained from R & D.
Anti-TIM-3 monoclonal antibody (RMT2-23) and rat IgG2a isotype control antibody (2A3) was
obtained from Bio-X-cell, West Lebanon, NH. Mouse and human recombinant galectin-9 was
provided by Gal Pharma, Japan. Galectin-3 was obtained from Sigma Chemical Co.
Recombinant human IL-2 and OVA323-339 peptide were obtained from Hemagen and Genscript
respectively. CFSE was obtained from Molecular Probe and used at a final concentration of 0.5
µM for 15 min. at 370C in PBS.
Corneal HSV-1 infection and clinical observations
Corneal infections of C57B/6 mice were conducted under deep anesthesia. Mice were
scarified on their corneas with a 27-gauge needle, and a 3-µl drop containing the required viral
dose was applied to the eye. The eyes were examined on different days postinfection (p.i.) with a
slit-lamp biomicroscope (Kowa, Nagoya, Japan), and the clinical severity of keratitis and
angiogenesis of individually scored mice was recorded as described elsewhere (15, 16).
Treatment of animals with anti-TIM-3 antibody and galectin-9
Six- to 8-wk-old C57B/6 mice were ocularly infected under deep anesthesia with either
5x105 PFU HSV RE Hendricks or 5x103 PFU of HSV I RE Tumpey and divided randomly into
groups. One group of animals infected with HSV I RE Hendricks was administered with 100µg
of anti-TIM-3 antibody intraperitoneally (i.p.) every alternate day starting from day 3 until day
13 p.i. Animals in control group were given isotype control antibody following same regimen.
Animals infected with HSV I RE Tumpey were given galectin-9 (10µg, 50µg or 100µg) ip
starting from day 3 until day 13 daily while control animals received diluent. In some
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experiments, 6-8µl of galectin-9 (1, 5 or 10µg) was injected sub conjuctivally into eye daily
starting either from day 4 or from day 8 until day 13. Galectin-9 was concentrated using Amicon
ultracentriguge devices (Millipore). Tubes were treated with N/10 NaOH and washed with sterile
PBS before using. Mice were observed for the development and progression of herpetic stromal
keratitis (SK) lesions and angiogenesis from day 5 until day 14, as described elsewhere (15, 16).
Most of the experiments were repeated at least three times unless stated
In vitro differentiation of CD4+CD25+Foxp3+ regulatory T cells and Th17 cells
Splenocytes isolated from DO11.10Rag2-/- mice were used as the precursor population
for induction of Foxp3 in CD4+ T cells as described elsewhere (17). Briefly, 2x106 of total
splenocytes after RBC lysis and several washings were cultured in 1 ml volume with previously
optimized doses of plate-bound anti-CD3 Ab (0.125 µg/ml in 200 µl volume), rIL-2 (25-100
U/ml), and TGF-β (2.5 to 10 ng/ml) for 5 days at 37°C in a 5% CO2 incubator in 48-well plates.
In some cultures in addition to IL-2, TGF-β either alone or in combination with various
concentrations of Galectin-9 was added. After 5 days, cells were characterized phenotypically by
flow cytometry.
For the differentiation of CD4+ T cells into Th17 cells, splenocytes isolated from
DO11.10 Rag2-/- mice were cultured with 10 µg/ml of OVA323-339 peptide, TGF-β (2.5 to 10
ng/ml), IL-2 (25U) and IL-6 (30-60 ng/ml) for five days. To look for the effect of galectin-9 on
Th17 cells, various concentration of galectin-9 or galectin-3 were added into cultures at the
beginning. After 5 days, cells were analyzed by intracellular cytokine staining for the production
of IL-17 and IFN-γ using BD bioscience kit. Foxp3 intranuclear staining was done using a kit
from eBioscience.

141

Proliferation assays
Splenocytes and DLN cells isolated from control and galectin-9 treated HSV infected
animals 14 dpi were labeled with 0.5µM of CFSE at 370C for 10 minutes. 5x105 of labeled cells
were cultured in presence of IL-2 (100U/ml), anti-CD3 (1µg/ml) and anti-CD28 (1µg/ml) mAb
for three days. After three days of incubation, dilution of CFSE was analyzed in stained Foxp3and Foxp3+ CD4+ T cells.
Ex vivo apoptosis assay
Draining lymph node cells and splenocytes isolated from uninfected and HSV infected
C57B/6 mice at 8 dpi were incubated with various concentrations of galectin-9 and galectin-3 for
8 hrs in 96 well flat bottomed plates in humidified incubators in presence of 5% CO2. After
incubation period was over cells, were stained for annexin V using a kit from BD Bioscience.
Additionally, cells were also co-stained for TIM-3 and Annexin V. Stained cells were analyzed
immediately by flow cytometry.
In vitro assays for VEGF production
A mouse stromal fibroblast cell line (MKT-1) kindly gifted by Dr Winston Kao,
Department of Ophthalmology, University of Cincinnati, Cincinnati, OH, was used for studying
the effect of galectin-9 on VEGF production. The cells were cultured in 10% DMEM and plated
onto 24 well tissue culture plates. The cells at more than 90% confluency were infected with
5MOI of HSV KOS for one hour. Thereafter, galectin-9 was added into the cells at various
concentrations. Untreated but infected cells served as positive control for these experiments. In
initial experiments cells were harvested at different times and stored in RNA stabilizing solution
obtained from Quiagen. For most of the subsequent experiments cells were harvested after 12
hrs.
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Real time RT-PCR
RNA was extracted from the cells stored in RNA later using RNeasy mini kit (Quiagen).
Total cDNA was made with 1µg of RNA using oligod(T) primer. Real time PCR was performed
using SYBR Green PCR Master Mix with iQ5 Real-Time PCR Detection System (BioRad,
Hercules, CA). VEGF expression levels of each samples were normalized to HPRT using ∆Ct
calculations. Relative VEGF expression between control and experimental groups were
calculated using 2-∆∆Ct formula. The sequences of the primers were: VEGF 5’ACACAGGACCGCTTGAAGAT-3’ and 5’-CTGCACCCACGACAGAAG-3’. HPRT 5’GACCGGTCCCGTCATGC-3’ and 5’-TCATAACCTGGTTCATCATCGC-3’.
ELISA
The corneal samples were pooled group wise and homogenized using a tissue
homogenizer (Pellet pestle mortar, Kontes). The concentrations of various cytokines and VEGF
was measured by sandwich ELISA kits from eBioscience (IL-6), and BD Bioscience (IL-12,
TGF-β) and Quantikine (VEGF-A). For TGF-β quantitation, samples were first acidified as per
manufacturer’s instructions.
Flow cytometric analysis
Cell preparation Single-cell suspensions were prepared from the cornea, draining
cervical lymph nodes (DLN), and spleen of mice at different time points p.i. Corneas and
trigeminal ganglia were excised, pooled group wise and digested with 60 U/ml Liberase (Roche
Diagnostics) for 60 min at 37°C in a humidified atmosphere of 5% CO2 as described earlier (17,
18). After incubation, the corneas and trigeminal ganglia were disrupted by grinding with a
syringe plunger on a cell strainer and a single-cell suspension was made in complete RPMI 1640
medium.
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Staining for flow cytometry The single-cell suspension obtained from LNs, spleen, and
corneal samples were stained for different cell surface molecules for FACS. All steps were
performed at 40C. Briefly, a total of 1x106 cells were first blocked with an unconjugated antiCD32/CD16 mAb for 30 min. in FACS buffer. After washing with FACS buffer, fluorochromelabeled respective Abs was added for 30 min. Finally, the cells were washed three times and
resuspended in 1% paraformaldehyde.
To enumerate the number of IFN-γ and TNF-α producing T cells, intracellular cytokine
staining was performed as previously described (18). In brief, 106 freshly isolated splenocytes,
lymph node cells were cultured in U bottom 96-well plates. Cells were left untreated or
stimulated with 2 MOI of UV inactivated HSV I and incubated overnight at 37°C in 5% CO2.
Brefeldin A (10 µg/ml) was added for the last five hours of the culture period. After this period,
cell surface staining was performed, followed by intracellular cytokine staining using a
Cytofix/Cytoperm

kit

(BD

PharMingen)

in

accordance

with

the

manufacturer's

recommendations. The Ab used were anti-IFN-γ-PE and anti-TNF-α-FITC. The fixed cells were
resuspended in 1% paraformaldehyde. For in vitro induced cultures, cells were stimulated with
PMA (50ng) and ionomycin (500ng) for 5 hours in presence of brefeldin A (10 µg/ml).
Subsequently, cells were first stained as described above for surface CD4 and intracellular
cytokines (IL-17 or IFN-γ). The stained samples were acquired with BD FACSCalibur and the
data were analyzed using the Flowjo software.
Statistical analysis
Most of the analyses for determining the level of significance were performed using
Student's t test. P ≤ 0.001 = *** P ≤ 0.01 = ** and P ≤ 0.05 = * were considered significant.
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Results are expressed as mean ± SD. For some experiments, as mentioned in the fig. legends, one
way ANOVA test was applied.

Results
TIM-3 expression is up regulated on T cells after HSV infection
As a prelude to exploring the value of manipulating TIM-3/galectin-9 interaction to
influence the outcome of stromal keratitis, mice were ocularly infected with HSV and the
expression pattern of TIM-3 on CD4+T cells was measured at various times in lymphoid tissues,
as well as the eye and trigeminal ganglion. Naïve animals lack inflammatory cells in the corneal
stroma but invasion by many cell types, including CD4+ T cells, is fully evident by day 8 p.i. At
this time, replicating virus is usually cleared, although the extent of the ocular inflammatory
response usually continues to progress and peaks in severity between 15 to 21 days (5).
Spontaneous regression, especially to a fully resolved state, usually does not occur without
treatment. The results in fig 4.1A and D record the frequency and numbers of CD4+TIM-3+ T
cells in the draining lymph nodes (DLN) and spleens at various times after HSV infection. In
naïve animals, few CD4+ T cells expressed TIM-3 (between 0.5 to 3.0% in different
experiments) and many that do were Foxp3+ (around 30 % of CD4+TIM-3+) (Fig 4.1C). By day
8, significant increases in the frequencies of TIM-3+CD4+ T cells were evident in both lymph
nodes and spleen. The pattern was similar on day 15 but by day 40 had declined markedly.
Analysis of lymph node and spleen cells at the time of peak responses revealed that most of the
TIM-3+CD4+ T cells expressed the activation marker CD44hi (Fig 4.1B). Although we lack the
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reagents to prove it, we suspect that the increased populations of TIM-3+CD4+ T cells were HSV
specific cells.
Ocular as well as trigeminal ganglion samples were also analysed using tissue pools
from several animals after collagenase digestion (Fig. 4.1E). At both time points examined,
around 50% of CD4+ T cells were TIM-3+. Taken together these results demonstrate that TIM-3
is up regulated on CD4+ T cells following HSV infection. This was especially evident at the
inflammatory ocular and trigeminal ganglia sites.
TIM-3 signaling may control stromal keratitis lesion severity
Studies on autoinflammatory lesions have indicated that TIM-3 signaling may represent a
mechanism by which lesions are regulated under physiological conditions (8, 11, 19). The results
expressed in figures 2A and B indicate that a similar situation likely occurs with HSV induced
ocular lesions. This was shown by comparing the outcome of ocular infection in mice given a
TIM-3 blocking monoclonal antibody (mAb) with those that received an isotype control mAb.
Treatment was begun 24 hours pi and the severity of HSK, as well as the extent of
neovascularization, compared over a 15 day observation period. The results were clear cut and
supported the notion that blocking TIM-3 led to enhanced HSV lesions and increased levels of
neovascularization (Fig. 4.2A and B). In two separate experiments involving 14 eyes, positive
SK lesions (a scores of ≥ 2) were evident earlier in mice that received anti-TIM-3 (8 out of 14
eyes positive at day 7) than those given the isotype control Ab (0 out of 14 eyes at day 7).
Lesions also became significantly more severe in anti-TIM-3 recipients with a higher percentage
of eyes showing positive lesions overall (12 out of 14 with scores of ≥ 2 and 10 out of 14 with a
score of ≥ 3 ) compared to isotype control Ab recipients (2 out of 14 with scores of ≥ 3) at day
14. A similar pattern of events was noted with the neovascularization scores.
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At day 15, experiments were terminated and corneas were pooled and collagen digested
to enumerate and phenotype the recovered cells. In addition, lymph nodes and spleens were
collected from animals with positive lesions to measure HSV specific immune responses. As
seen in figure 4.2C and D, the number of both CD4+ T cells and granulocytes was far greater in
the ocular samples from anti-TIM-3 treated animals than controls (a more than 10 fold increase
in CD4+ T cells and granulocytes). With regard to phenotype, the frequency of CD4+ T cells that
were TIM-3+ was far higher in the anti-TIM-3 MAb group (72% in one experiment) than in
controls (35%). The reason for this observation was not clear, but conceivably it could have
reflected the finding that the magnitude of anti-HSV CD4+ T cell responses was higher in the
anti-TIM-3 MAb treated animals (Fig 4.2E and F). Thus cells isolated from individual spleens
and draining LNs at 15 days p.i. of control Ab and TIM-3 antibody recipients, when stimulated
with HSV antigens and the numbers of IFN-γ and TNF-α producing cells measured, revealed a
2.5 fold increase in the frequencies and numbers of each of the cytokine producing cell
populations in anti-TIM-3 treated animals (Fig. 4.2E and F)
These results indicated that TIM-3 signaling of CD4+ T cells in lymphoid organs or
perhaps corneal lesions via its ligand under natural conditions may serve to regulate the extent of
stromal keratitis and that this may proceed at least in part by influencing the magnitude of the
immune response.
Galectin-9 Administration suppresses HSK lesions
Recently galectin-9 was shown to be the natural ligand of TIM-3 and that signaling via
galectin-9, at least to some T cell subsets, may cause them to undergo apoptosis (8). To evaluate
if the administration of galectin-9 could influence the expression of HSK, two types of
experiments were preformed in HSV ocularly infected mice. Animals were either treated i.p.
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with different doses of galectin-9 starting at day 4 or were given different doses of the drug
injected subconjunctively starting at day 4 or day 8 until mice were sacrificed to evaluate
different parameter at day 15. Both treatment modalities inhibited SK lesions as well as the
extent of neovascularization, but the efficacy of the local subconjunctival administration was the
greater (Fig 4.3A, B and C). The results shown in figure 4.3A demonstrated that following
systemic administration, significant levels of lesion inhibition were only observed at the highest
doses of galectin-9 evaluated (100µg) but a trend for suppressed lesions was evident at lower
doses.
With local administration of galectin-9, a dose dependent inhibition of SK lesions and
neovascularization also occurred with the differences compared to controls even more apparent
then observed with systemic administration (Fig 4.3B and C). Accordingly, in animals given
galectin-9 locally starting on day 4, lesions were reduced almost 3 fold on average compared to
untreated controls with these differences being highly significant (p ≥ 0.01 ). The numbers of
CD4+TIM-3+ cells recovered from eyes were significantly reduced compared to untreated
controls (Fig 4.4A). In addition the frequencies and numbers of PMNs were reduced 6-7 fold as a
consequence of galectin-9 treatment (Fig 4.4B and C). Along with clinical changes occurring in
response to local galectin-9 treatment, the levels of cytokines as well as the angiogenesis factor
VEGF were measured in pooled corneal extracts. As shown in Fig 4.4D, whereas levels of the
proinflammatory cytokines IL-6 and IL-12 were less, TGF-β levels were higher than in controls.
VEGF levels were also lower in galectin-9 treated pooled samples.
Of notable interest, if local treatment was begun on day 8, the time when lesions become
clinically evident, they failed to progress and even slightly diminished in severity compared to
untreated animals (Fig 4.3F). Furthermore, as shown in fig. 4.4E, pooled corneal samples from
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treated animals had lower levels of proinflammatory (IL-6) and higher levels of antiinflammatory (TGF-β). These data strongly indicate that TIM-3/galectin-9 interaction serves to
induce resolution of viral immunoinflammatory lesions.
Possible mechanisms by which galectin-9 therapy functions
Induction of apoptosis of TIM-3+CD4+ T cells
Prior in vitro studies have indicated that galectin-9 triggering of proinflammatory CD4+ T
cells causes them to undergo apoptosis (8). Since in the HSK model, lesions appeared to be
mainly orchestrated by IFN-γ producing CD4+ T cells (6), lesions could be reduced if
orchestrating T cells were destroyed. We attempted to demonstrate such an effect in vivo by
examining single cell suspensions from lymphoid organs by flow cytometry or tissue sections of
treated eyes for signs of apoptotic cells. Such could not be demonstrated (data not shown).
However, it was evident that the total numbers of CD4+ T cells as well as HSV-specific
CD4+IFN-γ+ T cells were significantly reduced in animals treated systemically with galectin-9
which could have been the consequence of apoptosis (Fig 4.5A). In addition, we were able to
demonstrate CD4+ T cells that express TIM-3 as a consequence of HSV infection in vivo could
be induced to undergo apoptosis when exposed to galectin-9 in vitro (Fig 4.5B-D).
As TIM-3 expression was also evident on about 10-15% of Foxp3+CD4+ T in lymphoid
organs, we investigated if these cells are also susceptible to killing by galectin-9 ligation. Thus,
DLN cells were isolated from either infected or uninfected GFP-Foxp3 knock-in animals and
treated with various doses of galectin-9 in vitro for eight hours. As shown in fig 4.5B, while
more than 90% of CD4+TIM-3+Foxp3- cells underwent apoptosis, less than 10% of CD4+TIM3+Foxp3+ T cells were annexin V+. Furthermore, CD4+TIM-3+Foxp3+ T cells showed minimal
level of expression of annexin V on their surface as measured by the mean fluorescence
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intensity. This could mean that as a consequence of galectin-9 treatment with Foxp3+ cells
showing more resistance to apoptosis, the ratio of Tregs: Teffector would increase perhaps
accounting in part for the anti-inflammatory effect of galectin-9.
Expansion or induction of Foxp3+ Tregs
Prior experiments have established that the severity of HSK lesions can be modulated by
Foxp3+ regulatory T cells either induced in vivo or by adoptive transfers of such cells (15, 17).
There is some indirect evidence that galectin-9 could be involved in the induction of Foxp3+
cells since such cells were reduced in numbers in galectin-9 knockout animals (12). To
determine if galectin-9 administration to HSV infected animals had any influence on the Treg
response, experiments were done in which animals were infected with HSV after which from day
4 to day 14 one group was injected systemically with a dose of galectin-9 shown to be effective
at diminishing lesion severity and the other group received diluent. Experiments were terminated
on day 15 and the cell types in individual DLN and spleen were collected to quantify CD4+ T
cells that were Foxp3+. As shown in Fig. 4.5E and F, significant increases (P ≥ 0.05) in the
frequencies and numbers of CD4+Foxp3+ T cells were evident in the spleens of galectin-9 treated
animals. Additionally the numbers of Foxp3+ cells in the DLNs of galectin-9 treated animals
were also increased, but the numbers compared to controls were not significant. This effect of
galectin-9 treatment might be the consequence of expansion of preexisting Foxp3+ cells or
perhaps conversion of some Foxp3- cells to become Foxp3+.
Evidence that galectin-9 could be causing some expansion of Foxp3+ cells was shown by
comparing the proliferative capacity in vitro of Foxp3+ cells from control and galectin-9 treated
animals. As shown in fig. 4.5G, CFSE dilution in Foxp3+ cells TCR stimulated for 3 days, in the
presence of IL-2 was greater in the cell population from galectin-9 treated animals than from
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controls. Curiously, the effect of galectin-9 treatment on the response of Foxp3- cells was to
diminish their proliferation capacity compared to that occurring in the same cell population from
controls. These observations support the concept that the enrichment of Foxp3+ cells in galectin9 treated animals could in part be explained by expansion of previously Foxp3+ cells.
Galectin-9 may promote Foxp3+ Treg conversion and limit Th17 generation in vitro
To directly assess whether or not galectin-9 can cause some TCR stimulated conventional
T cells to become Foxp3+, an in vitro culture system was used which in previous studies
demonstrated Foxp3+ conversion (17). Briefly, splenocytes from DO11.10 RAG-/- animals (that
lack Treg) were stimulated in vitro with plate bound anti-CD3 antibody, optimal amounts of IL-2
and various doses of galectin-9. TGF-β at optimal amounts was used instead of galectin-9 as a
positive control system for Foxp3+ Treg induction. In such experiments galectin-9 did cause
significant numbers of cells to convert to become Foxp3+ although the conversion was around
four to five fold less effective than occurred with TGF-β (Fig. 4.6A and B). When experiments
were done using suboptimal amounts of TGF-β, the addition of galectin-9 increased the
conversion beyond the various doses of galectin-9 in the absence of TGF-β. This observation
may mean that galectin-9 might be inducing TGF-β in the cultures which in turn could enhance
the conversion efficiency although this needs to be formally confirmed.
In another approach splenocytes from DO11.10 RAG-/- animals, were cultured in
conditions that resulted in the induction of Th17 cells. Basically such cultures were OVA323-339
stimulated whole splenocytes in the presence of IL-2, TGF-β and IL-6. Curiously, the addition of
galectin-9 in these cultures inhibited the induction of Th17 cells in a dose dependent manner (Fig
4.6C and D). It was of particular interest to note that the addition of galectin-9 in these cultures
increased the production of Foxp3+ cells up to four fold. The results could mean, however, that
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the anti-inflammatory effects of galectin-9 will not be negated by the presence of
proinflammatroy cytokines such as IL-6 in the inflamed tissue. We did not investigate the
mechanism of Th17 suppression, but conceivably it could involve galectin-9 apoptosis signals
delivered to TIM-3 expressed by developing Th17 cells. We are currently attempting to verify
this.
Expansion of Myeloid suppressor cells
It was of interest to note that galectin-9 treated animals, as compared to control animals
showed significantly expanded populations of CD11b+ cells especially in the spleens (Fig. 4.7A
and B). As shown in the fig 4.7C-E, a significant proportion of these cells also expressed
Gr1lo,F4/80+ and Ly6Chi a phenotype possessed by myeloid suppressor cells which have been
shown to inhibit the function of conventional CD4+ and CD8+ T cells (20, 21). Interestingly, the
frequencies of cells of this phenotype also increased in when galectin-9 treatment was performed
locally in the corneas of infected animals (Fig. 4.4B and C). Future studies will attempt to
measure if the myeloid suppressor cells play any regulatory effect in HSK.
Taken together our results may indicate that a consequence of galectin-9 therapy is that
there is an overall increase in the frequency of regulatory cells that include both Foxp3+ Tregs
and CD11b+Gr1loF4/80+Ly6Chi myeloid suppressor cells. Expanded population of Foxp3+ Tregs
may represent conversion of conventional cells to become Treg and perhaps reflect a
disappearance of CD4+ Th1 cells because many TIM-3+ cells are triggered to die by apoptosis.
Galectin-9 may also inhibit the production of angiogenic factors
As indicated above, galectin-9 treatment of HSV infected mice also led to a reduction in
the extent of ocular neovascularization. Indeed there was a trend for the effect on this necessary
step in HSK pathogenesis to be greater than was observed on SK lesion severity (Fig 4.3D). This
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effect could be explained by the fact that some angiogenic factors derive from the inflammatory
cells themselves and these responses were reduced in galectin-9 treated animals. Alternatively,
galectin-9 might have some direct inhibitory effects on cells in the eye that produce angiogenesis
factors in response to infection. To mimic the latter possibility, the effects of galectin-9 on the
induced production of VEGF-A mRNA in stromal fibroblast cell line was measured. These cells
can be induced to produce the angiogenic factor VEGF-A upon exposure to IL-6 or HSV
infection (22). Experiments were performed in which MKT-1 cells were exposed to a high
multiplicity of HSV-KOS (5MOI) which resulted in cells upregulating VEGF-A mRNA (Fig.
4.8). This increase which reached 1800 fold in some instance, was suppressed up to 100 fold by
galectin-9. Similar doses of galectin-3 were almost without inhibitory effects. These results
support the possibility that galectin-9 can function as an angiogenesis factor inhibitor although it
must mediate its function by binding to a receptor distinct from TIM 3 since the latter molecule
was not detectable on the MKT-1 cells (data not shown).

Discussion
Controlling chronic immunoinflammatory diseases represents a major therapeutic
challenge. Such an example is lesions in the eye caused by HSV infection which commonly
result in blindness. These lesions are strongly suspected to result from T cell mediated responses
to the infection. Since the main T cell subset responsible for orchestrating lesions of stromal
keratitis appear to be CD4+ T cells of Th1 type with perhaps some involvement by Th17CD4+ T
cells, a logical approach to therapy would be to suppress or delete the function of activated CD4+
T cell subsets and increase the representation of cells that express regulatory function. We show
in this report that this outcome can be achieved by therapy systemic or local with the lectin
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family member galectin-9. This molecule, which is natural product of cell types such as several
cells of innate immune system, endothelial, epithelia cells etc., acts as a ligand to the inhibitory
molecule TIM-3 that is expressed by activated but not naïve T cells. We show that 50% or more
of T cells in ocular lesions caused by HSV in mice express TIM-3 and that blocking signals from
its natural ligand with a monoclonal antibody results in more severe lesions. More importantly,
however, the provision of additional galectin-9 either systemically or more effectively by local
subconjuctival administration diminished the lesion severity of SK lesions as were the extent of
corneal neovascularization. The mechanisms by which the galectin-9 therapy functioned were
shown to be multiple. These involved apoptosis of the orchestrating effecter T cells with
consequent reduction of proinflammatory cytokines, an increase in the representation of two
separate subtypes of regulatory cells as well as inhibitory effect on the production of molecules
involved in ocular neovascularization, an essential component of HSK pathogenesis. Our results
indicate that galectin-9 therapy may represent a useful approach to control HSV induced lesions,
the commonest infectious cause of blindness in the Western World.
A number of previous reports have shown that activated T cells, both CD4+ and CD8+ T
cells (8, 13), may up regulate TIM-3 and that the engagement of the receptor with its ligand
galectin-9 causes cells to undergo apoptosis (23). Since galectin-9 is a product of several cell
types with its production increased upon exposure to some cytokines released from activated T
cells, the TIM-3/galectin-9 interaction may represent a physiological means by which effector T
cell responses are terminated (8, 11). Thus the severity of some autoimmune inflammatory
responses may be more severe in galectin-9 knock out animals (12). Also of therapeutic
relevance, it has been observed that administration of galectin-9 may suppress the severity of
some autoimmunities even when given quite late in the disease process (12). Our studies too,
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which we believe are the first to investigate the relevance of TIM-3/galectin-9 in a chronic viral
induced inflammatory disease, galectin-9 administration caused the suppression of HSK lesions
even when the drug was given 8 days after virus infection. At this stage, virus is usually no
longer present in the eye although without treatment lesions continue to advance in severity and
usually do not resolve spontaneously. In some instances we observed that galectin-9 therapy did
cause almost complete resolution.
We presume that the efficacy of galectin-9 therapy resulted from causing apoptosis of the
CD4+ T cells responsible for orchestrating lesions. However, we failed to show any evidence of
T cell apoptosis in vivo which may not be too surprising since apoptotic cells are rapidly
phagocytosed in vivo (24, 25). We could readily show apoptosis of TIM-3+ cells in populations
of lymphoid cells taken from HSV infected animals when exposed to galectin-9 in vitro.
However in such experiments, many TIM-3 positive cells resisted apoptosis even at highest
doses of galectin-9 investigated. Curiously, in our in vitro studies we observed that TIM3+Foxp3+CD4+ T cells showed more resistance to galectin-9 induced apoptosis than did Foxp3CD4+TIM-3+ T cells. The molecular explanation for this interesting observation is currently
under further investigation. However, if it turns out that Foxp3+ regulatory T cells are more
resistant to galectin-9 induced apoptosis in vivo, this might explain why the treatment resulted in
suppressed SK lesions. Thus, as we have shown previously, the Treg response serves to
modulate the severity of SK lesions (18). Differential susceptibility of T effectors to Treg would
result in Treg enrichment. In line with this, we did observe that frequencies of Foxp3+ T cells in
lymphoid tissues as well as ocular inflammatory populations were increased in galectin-9 treated
infected animals. That galectin-9 administration may result in the apparent induction of Foxp3+
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regulatory T cells was also reported recently by Seki et al although the mechanisms responsible
for the effect were not investigated (12).
In our studies, we observed that galectin-9 could affect the Treg responses by mediating
at least two effects in addition to the differential susceptibility to apoptosis. Accordingly, we
could show that the proliferative capacity in vitro of TCR stimulated Foxp3 cells was greater in
population taken from galectin-9 treated compared to control animals. However, perhaps of more
importance we could also demonstrate that galectin-9 was able to induce conventional naïve
TCR stimulated CD4+ T cells to convert to become Foxp3+. This was shown using TCR
transgenic T cells TCR stimulated in vitro in the presence of galectin-9. Significant levels of
conversion were observed, although this was less than that could be achieved with optimal doses
of TGF-β. In fact our results could mean that the galectin-9 conversion effect involved the
production of TGF-β, since when cells were stimulated in the presence of suboptimal levels of
TGF-β, galectin-9 addition caused higher levels of conversion than could be achieved with
galectin-9 or TGF-β alone. However, at present other possibilities can not be ruled out.
Whether or not galectin-9 administration succeeds in converting conventional cells to
become Foxp3+ and their expansion in vivo is currently under investigation. If it does occur, it
might help explain why some parasitic infections appear to be potent inducers of Treg response,
which in turn play an important role during pathogenesis (26, 27). Thus, many parasites express
high levels of lectins that include galectin-9 in their surface components (27). Furthermore,
galectin-9 is expressed abundantly in the gut mucosa (28) which is a site where the peripheral
generation of regulatory T cells readily occurs (29-31). The presence of galectin-9 may help
counteract an inflammatory environment that favors the induction of Th17 cells as we were able
to demonstrate in our in vitro studies.
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Whereas previous reports have noted that the TIM-3/galectin-9 interaction can have a
notable effect on inflammatory cell function, any effect on angiogenesis was not noted. In our
study, we observed that galectin-9 administration had an even greater effect on angiogenesis than
it did on the severity of the SK lesions. The reasons for this may be that galectin-9 may be
inhibiting the production of angiogenesis factors such as VEGF responsible for causing the new
blood vessel development that plays an essential part of SK pathogenesis. Exactly how galectin-9
causes its inhibitory effects on angiogenesis factor induction still require further investigation. Of
particular interest in our model systems, we demonstrated an inhibitory effect of galectin-9 on
the induced production of VEGF from cells that lacked demonstrable TIM-3.
Taken together our results are consistent with the observation that the TIM-3/galectin-9
interaction plays a critical role at influencing the expression of HSV induced ocular lesions. It
seems likely that the interaction affects lesion severity under normal circumstances since lesions
become more severe if signals from endogenous galectin-9 are blocked with anti-TIM-3 mAb.
Moreover, the interaction can be exploited for therapeutic purposes since treatment with
galectin-9 can diminish lesions and can even result in their resolution. The mechanisms by which
therapy succeeds are multiple and involve a change in balance between proinflammatory effector
cells and regulators as well as effects on the production of angiogenesis factors responsible for
causing neovascularization of the eye.
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Figure 4. 1 Kinetic analysis of TIM-3 expression on CD4+ T cells after ocular HSV
infection.
C57B/6 mice were infected with 5x103 of HSV. Three animals were sacrificed at each indicated
time point and their spleens and draining cervical LN cells were analyzed for surface expression
of CD4 and TIM-3 by flow cytometry. A. Histogram showing the percent of CD4+TIM-3+ T
cells in spleen and DLN at indicated time points is shown. Data are shown from one
representative experiment. B. Dot plot shows the expression of TIM-3 on CD4+CD44hi T cells.
C. The expression of TIM-3 on CD4+Foxp3-GFP+ and CD4+Foxp3-GFP- from uninfected and
HSV infected animals at 8dpi. D. Absolute numbers of TIM-3+CD4+ T cells in spleen and DLNs
at indicated time point are shown. The expression of TIM-3 on CD4+ T cells isolated from
inflamed pooled corneas and trigeminal ganglia at day 8 and day 15 post infection is shown. All
kinetic experiments were repeated at least two times.
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Figure 4. 2 Effect of TIM-3 blockade on corneal inflammation and CD4+ T cell immune
response.
C57B/6 animals (n=8) infected with 5x105 PFU of HSV were given either anti-TIM-3
monoclonal antibody (n=4) or isotype control antibody (n=4) every alternate day starting from
day 3 until day 13. The disease progression and immune parameters at day 14 were analyzed. A.
The SK lesion severity and magnitude of angiogenesis is shown. B. Cumulative scores of lesion
severity and angiogenesis at 14 days post infection. C. Percentages and phenotype (surface TIM3) of CD4+ T cells in the corneas of control (upper panel) and antibody treated (lower panel)
animals is shown D. CD11b+Gr1+ PMN infiltrated into cornea of control (upper panel) and
antibody treated (lower panel) animals is shown. E. HSV-specific CD4+ T immune response in
control and anti-TIM-3 antibody treated animals is shown at day 14. Dot plots depicting the
percentages of IFN-γ+ TNF-α+ CD4+ T cells is shown. F. Total number of HSV-specific
CD4+IFN-γ

+

and CD4+IFN-γ+TNF-α+ T cells in spleen and DLN at day 14 is shown. The

experiments were repeated three times. Student ‘t’ test was used to calculate the level of
significance.
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Figure 4. 3 Effect of galectin-9 treatment on the severity of SK.
C57B/6 animals (n=12) infected with 5x103 PFU of HSV were treated with galectin-9 (10μg,
50μg and 100μg) daily starting from day 4 until day 14. A. Lesion and angiogenesis scores of
control and galectin-9 treated animals at day 14 are shown. B. C57B/6 animals (n=9) infected
with 5x103 PFU of HSV were injected subconjuctivally with 1µg, 5µg or 10µg of galectin-9
daily starting from day 4 until day 13. Lesion and angiogenesis scores of control and treated
animals at day 14 are shown. C. The comparative lesion scores of HSV infected animals at 14
dpi when treated with galectin-9 either 10μg sub-conjuctivally or 100μg i.p. is shown D. The
comparative reduction in lesion severity and angiogenesis scores of HSV infected animals
treated locally with 10µg of galectin-9 daily is shown. E. Therapeutic effect of galectin-9 (10µg)
administration on SK in C57B/6 animals infected (n=8) with 5x103 PFU of HSV. Kinetics of
lesion and angiogenesis expression in control and galectin-9 treated animals (8-14 days pi) at 15
dpi is shown. All experiments were repeated at least three times. Data was analysed using one
way ANOVA test with Dunnett’s post settings except in E where Student ‘t’ test was used.
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Figure 4. 4 Effect of galectin-9 treatment on cellular infiltration and cytokine levels in
corneas of HSV infected animals.
C57B/6 animals infected with 5x103 PFU of HSV were given 10μg of galectin-9
subconjuctivally daily starting from day 4 until day 13 as described above in Fig 3B. A. Total
numbers of CD4+ and CD4+TIM-3+ T cells in the corneas of control and galectin-9 treated
animals is shown at day 14. B-C. The frequencies and numbers of infiltrated PMNs
(CD11b+Gr1hi) and a cell type akin to MSCs (CD11b+Gr1lo) is shown in control and galectin-9
treated animals. D. Levels of cytokines (IL-6, TGF-β and IL-12) and angiokine (VEGF-A) in
pooled corneal samples each consisting of four cornea/group isolated from control and galectin-9
treated animals as analyzed by sandwich ELISA are shown. E. Levels of IL-6 and TGF-β in
pooled corneal samples isolated from control and therapeutically treated HSV infected animals
are shown. Experiments were repeated twice. Statistical levels of significance were estimated by
Student’s ‘t’ test
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Figure 4. 5 Differential effect of galectin-9 therapy on regulatory T cells and effector CD4+
T cells in HSV infected animals.
A. Total numbers of CD4+ T cells and CD4+IFN-γ+ T cells in the DLNs and spleens of control
and galectin-9 treated (systemic) animals in shown. B-D. Induction of apoptosis of CD4+Foxp3TIM-3+ T cells by galectin-9. Cells isolated from cervical LNs of HSV infected Foxp3-GFP
knock in animals (day 8) and uninfected animals were cultured in the presence of PBS, galectin3 and galectin-9 for 8 hours and thereafter stained for annexin-V, B. Annexin-V+CD4+Foxp3and Foxp3+ T cells isolated from infected (upper panel) and uninfected (lower panel) animals
incubated with PBS and galectin-9 animals is shown. C. The bar diagram showing the
percentages of annexin-V+ cells under indicated conditions is shown. D. Co-staining of CD4+ T
cells for annexin-V and TIM-3 is shown. E-G. Proliferative responses of Foxp3- and
Foxp3+CD4+ T cells in HSV infected animals after galectin-9 therapy. Frequencies (E) and
absolute numbers (F) of CD4+Foxp3+ T cells in the spleens (E and F) and DLNs (F) of control
and galectin-9 treated animals are shown. G. DLN cells isolated from control and galectin-9
treated animals were labeled with CFSE and their proliferative response in the presence of antiCD3 and anti-CD28 were analyzed after 3 days. CD4+ gated population analyzed for the dilution
of CFSE in Foxp3+ and Foxp3- CD4+ T cells from control (thin line) and galectin-9 treated (thick
line) animals is shown.
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Figure 4. 6 Effects of galectin-9 treatment on the generation of CD4+Foxp3+ regulatory T
cells and Th17 cells in vitro.
Splenocytes isolated from DO11.10RAG2-/- animals were cultured with IL-2 alone, IL-2+TGFβ 2ng/ml, IL-2+Galectin-9, IL-2+TGF-β+galectin-9, IL-2+TGF-β +IL-6 with or without
galectin-9. A. Representative FACS plots from more than 6 experiments showing the Foxp3
induction in TCR stimulated CD4+ T cells isolated from DO11.10RAG2-/- animals under
indicated conditions. B. The bar diagram shows the percentage of CD4+ T cells expressing
Foxp3 under indicated conditions. The levels of significance was calculated by ANOVA test C.
Cells were cultured under Th17 differentiating conditions (IL-2+TGF-β +IL-6) with or without
galectin-9. The dot plots show the inhibitory effects on the generation of Th17 cells (upper
panel) and the stimulatory effects on the generation of Foxp3+ T cells (lower panel) of various
doses of galectin-9 in in vitro cultures. D. The bar diagram shows the percentages of Th17 or
Foxp3+ Tregs induced under indicated conditions. The experiments were repeated at least four
times and the level of significance was determined by Student ‘t’ test.
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Figure 4. 7 Effects of galectin-9 administration on CD11b+ myeloid suppressor cells.
C57B/6 animals infected with 5x103 PFU of HSV were treated i.p. with 100μg of galectin-9
daily starting from day 4 until day 14 as described in Fig 4.3A and CD11b+ cells from control
and galectin-9 treated animals were phenotypically characterized at day 15 post infection. A-B.
FACS plots (A) and bar diagram (B) depicting the percentages of CD11b+ cells in the spleens of
control and galectin-9 treated animals at day 14 are shown. C-D. Phenotypic characterization of
CD11b+ cells from control and galectin-9 treated animals with respect to the expression of Gr1,
F4/80, CD11c and Ly6C is shown. C. Bold lines in hitograms in D show the expression of the
indicated marker on CD11b+Gr1lo gated population while thin lines show the expression of
indicated surface molecules on CD11b+Gr1hi gated population from the spleens of galectin-9
treated animals. E. Total numbers of cells in gated CD11b+Gr1hi and CD11b+Gr1lo cells in the
spleens of control and galectin-9 treated animals as shown in C. Student ‘t’ test was used to
calculate significance level between groups.
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Figure 4. 8 Effects of galectin-9 on VEGF-A production.
MKT (stromal fibroblast cell line) cells were used to observe the effect of galecetin-9 on VEGF
production. The cells were infected with 5MOI of HSV KOS and were then treated with various
doses of galectin-9. A VEGF-A mRNA expression was measured at 6 hours and 12 hours from
control and galectin-9 (1μg, 10μg and 50μg/ml) treated cells as normalized with HPRT
expression is shown. One was ANOVA was used to calculate the level of significance.
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